Military reference books and manuals (2009-2023, Volume 4)

Azerbaijan Evacuee Management Plan

Page 51 of 56

ERP - Media Representative

Azerbaijan SPU Evacuee Management Checklists

SECTION 4 - 4.7.15

Function

Srl.

Objectives

Time



Initial

Obtain briefing from HR-ESG Manager/Public Information Officer IMT (Command Staff)

(Ensure this includes info on location of ERP and the Point of Contact at ERP.).

Actions

Always wear your ID Badge.

Obtain briefing from ERP Manager.

Set up Media office (With Site Coordinator).

Maintain contact with Public Information Officer IMT (Command Staff).

Evacuation

Ensure all new press releases are forwarded to ERP Manager for distribution to team members, briefing

of evacuees and relatives and display on notice boards.

Reception

Maintain liaison with contractor representatives (if present).

Point

Be prepared to take media queries at ERP.

Regularly update ERP Manager/Site Coordinator.

Log all actions and submit to ERP Administration Unit.

Control Tier:

Revision Date: 1 September 2010

Document Number: AZSPU-HSSE-DOC-00149-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING.

THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

Azerbaijan Evacuee Management Plan

Page 52 of 56

Appendixes

Appendix 1 - Hospital Location List

Hospital Location List

(eng)

(aze)

(ru)

Appendix 2 - Initial Reception Point Evacuees Briefing Guidance

IRP Ev Briefing

Guidance (eng)

Guidance (aze)

Guidance (ru)

Appendix 3 - Joint Security Guidelines

Joint Security

Guidelines (eng)

Guidelines (aze)

Guidelines (ru)

Appendix 4 - Evacuation Reception Point Evacuee Briefing Guidance

ERC Ev Briefing

Guidance (eng)

Guidance (aze)

Guidance (ru)

Control Tier:

Revision Date: 1 September 2010

Document Number: AZSPU-HSSE-DOC-00149-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING.

THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

Azerbaijan Evacuee Management Plan

Page 53 of 56

Appendix 5 - Down Manned Personnel Guidance

Down Manned Pers

Guidance (eng)

Guidance (aze)

Guidance (ru)

Appendix 6 - Personnel Tracking Form

Personnel Tracking

Form (eng)

Form (aze)

Form (ru)

Appendix 7 - Forms Tracking Process and Guidance

Form Tracking Proces

and Guid (eng)

and Guid (aze)

and Guid (ru)

Appendix 8 - Relevant Contact Numbers

Relevant Contact

Numbers (eng)

Numbers (aze)

Numbers (ru)

Appendix 9 - Travel and Accommodation Booking Form

Travel Booking Form

(eng)

(aze)

(ru)

Control Tier:

Revision Date: 1 September 2010

Document Number: AZSPU-HSSE-DOC-00149-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING.

THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

Azerbaijan Evacuee Management Plan

Page 54 of 56

Appendix 10 - Evacuation Reception Point Relatives Briefing Guidance Notes

ERC Rel Briefing

Guidance (eng)

Guidance (az).doc

Guidance (ru)

Appendix 11 - Next of Kin Tracking Record

NOK Tracking Record

(eng)

(aze)

(ru)

Appendix 12 - Disclaimer Form

Disclaimer (eng)

Disclaimer (az)

Disclaimer (ru)

Appendix 13 - Evacuee Management Plan Aide Memoir

Aide Memoir (eng)

Aide Memoir (aze)

Aide Memoir (ru)

Appendix 14 - Evacuee Management Plan For Midstream PU

EMP for Midstream

Control Tier:

Revision Date: 1 September 2010

Document Number: AZSPU-HSSE-DOC-00149-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING.

THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

Azerbaijan Evacuee Management Plan

Page 56 of 56

Revision/Review Log

Revision Date

Authority

Custodian

Revision Details

July 1, 2008

Sue Adlam-Hill

Narmina Sadikhova

Initial Issue July 1, 2008

HR Vice-President

Business Continuity

Planning Advisor

October 30, 2009

Sue Adlam-Hill

Narmina Nabiyeva /

Contact numbers have

HR Vice-President

HR Manager Finance

been updated in the

& C&EA

procedure

Minor formatting made

September

Sue Adlam-Hill

Vugar Ibrahimov/ HR

Certain Titles changed

01,2010

HR Vice-President

ER Manager

Minor formatting made

Expansion of procedure

Control Tier:

Revision Date: 1 September 2010

Document Number: AZSPU-HSSE-DOC-00149-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING.

THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 2 of 31

Introduction

The purpose of this medical response plan is to:

 provide guidance for a timely, consistent and coordinated medical response across BP Az SPU in the

event of an influenza pandemic;

 provide necessary medical guidance for BP Az SPU medical advisers to support staff and dependents;

 minimise the impact of a pandemic and seek to maintain essential company operations.

Background

Influenza is a viral respiratory disease affecting humans and certain animals. Clinical disease ranges from mild

non-specific illness to life threatening pneumonia and death, depending on the nature of the influenza strain

involved and the person or animal species infected. Human influenza is classically a recurrent seasonal illness

which breaks out at various times of the year in different continents (for example, typically late winter and

spring in temperate countries of the Northern hemisphere).

Although seasonal human influenza is certainly responsible for some excess seasonal mortality every year all

over the world (particularly at the extreme ages of the life and chronically ill), the usual mortality rate is

relatively low, and only minimal disruption of essential services occurs during a normal influenza season.

However, when a completely new strain of influenza emerges among human populations, mortality rates can be

much higher than usual (generally from severe respiratory disease), spread can be nearly universal (sometimes

within a matter of months) with disruption of all sectors of society. Such a situation is called a “pandemic."

Historically, influenza pandemics have spread in waves, rapidly encircling the globe and then subsiding after

around 2 years or so. If an influenza pandemic appears, we could expect the following:

 Given the high level of global traffic, the pandemic virus will spread rapidly, leaving little time to

prepare.

 The 1918 pandemic caused the largest impact in previously healthy young adults. Should this pattern

be repeated in the next pandemic, it would have a substantial impact on the workforce.

 Vaccines, antiviral agents and antibiotics to treat secondary infections may be in short supply and may

be unequally distributed. It will take several months before any effective pandemic vaccine becomes

widely available.

 Medical facilities will be overwhelmed and health care workforce is likely to be reduced because of

increased exposure and illness.

 Widespread illness may result in shortages of personnel to provide essential community services.

More backg1round information on influenza is available at:

 Pandemic Influenza:

http://www.who.int/csr/disease/influenza/pandemic/en/

http://www.pandemicflu.gov/

 Influenza A (H1N1):

http://www.who.int/csr/disease/swineflu/en/index.html http://www.cdc.gov/h1n1flu/

 Avian

influenza

(H5N1):

http://www.who.int/csr/disease/avian_influenza/en/

http://www.cdc.gov/flu/avian/index.htm )

 Influenza:

http://www.who.int/topics/influenza/en/

http://www.cdc.gov/flu/

1.0

Medical Response Plan

The BP Az SPU medical response plan contains information on the medical response required at each stage of

the BP strategies. It also includes isolation and quarantining measures to reduce the risk of influenza

transmission.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 3 of 31

Section 1 - Implementing the Medical Response Plan

This Section contains the specific recommended action points to be considered for each of the WHO

Pandemic Phases referred to in the WHO Global Influenza Preparedness Plan (2009)*.

The Section also indicates who should be accountable for each action including:

 Head-of-Country/Business Unit Manager (abbreviated as “HoC/BU”)

 Facilities Manager (abbreviated as “FM”)

 Health Manager (abbreviated as ”HM”)

 Health Adviser (abbreviated as “HA”)

 Individual (abbreviated as “ID”)

In addition to the WHO Pandemic Phases referred to above, BP has developed a series of “Leading

Indicators” which may be used as a guide to initiate implementation of the pandemic response plans,

subject to Head-of-Country approval and endorsement by the BP AzSPU Health Manager.

Name

Almaz Agazade

Role

Health SPA

job title

AzSPU Health Manager

Phone number:

+ 99455 4252253 (mobile

Responsibilities

Activate and manage Medical Pandemic Response

Alternative:

Health Advisor

Plan

Manage the medical contractors during the incident

Ensure availability and accessibility of secondary

care facilities

Ensure that all medical resources are available for

immediate use

Ensure isolation procedures are implemented as

appropriate

The PU Health advisers should work with the Az SPU Health Manager to apply Group Policies locally.

* WHO Pandemic Phases (Global Influenza Preparedness Plan, 2009 revision)

In the 2009 revision of the Pandemic Phase descriptions, WHO has retained the use of a six-phased

approach (contained in the 2005 plan) for easy incorporation of new recommendations and approaches

into existing national preparedness and response plans (see figure below). The grouping and description

of pandemic phases have been revised to make them easier to understand, more precise, and based

upon observable phenomena. Phases 1-3 correlate with preparedness, including capacity development

and response planning activities, while Phases 4-6 clearly signal the need for response and mitigation

efforts. Furthermore, periods after the first pandemic wave are elaborated to facilitate post pandemic

recovery activities.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 5 of 31

The following table shows the actions for implementation of the BP medical plan for influenza pandemic. For

each influenza pandemic phase, as declared by WHO, it outlines specific measures to be considered by Head-

of- Country/Business Unit Manager ( HoC/BU), Facilities Manager (FM), Health Manager(HM)/Health

Adviser (HA) and Individual (ID).

“Affected” means countries where the “novel” influenza virus subtype is

present in animals (as per WHO).

WHO PANDEMIC PHASES

Location of

Specific action points

Action

event

(2009 revision)

(Country)

Phase 1-3 - Predominantly Animal Infections: Few Human Infections

In Phase 1 no viruses circulating among

Any affected

- Prepare influenza pandemic medical

HA/HM

animals have been reported to cause

or not yet

response plans

infections in humans.

affected

- Promote the increased use of seasonal

influenza vaccine (see Guideline 3)

In Phase

2 an animal influenza virus

Any affected

In addition to the above:

circulating among domesticated or wild

or not yet

- Issue guidance to minimise the risk of

animals is known to have caused

affected

exposure to animal and human

infection in humans, and is therefore

influenza (see Guideline 1 & 2)

HoC/BU

considered a potential pandemic threat.

- Assess availability of antivirals and

HoC/BU

priorities for supply

Assess availability of other

medications and personal protective

FM/HA

equipment (PPE) for medical staff (see

Guideline 4)

- Review infection control procedures

at workplace and clinics

- Monitor the development of a human

vaccine against the strain

In Phase 3 an animal or human-animal

Any affected

In addition to the above:

influenza reassortant virus has caused

or not yet

- Monitor reported cases in affected

sporadic cases or small clusters of

affected

areas

HoC/BU

disease in people, but has not resulted in

- Check stocks of antivirals and prepare

human-to-human transmission sufficient

distribution and dispensing plans for

to sustain community-level outbreaks.

FM/HA

both routine and accelerated issue (see

Limited human-to-human transmission

Section 3)

may occur under some circumstances, for

example, when there is close contact

- Check stocks of personal protective

equipment

(PPE) for medical staff,

between an infected person and an

unprotected caregiver. However, limited

respiratory cases, travellers; personal

thermometers for

“self-monitoring”;

transmission under such restricted

circumstances does not indicate that the

and essential respiratory medications

(e.g. antibiotics) for treatment of cases

virus has gained the level of

transmissibility among humans necessary

(see Guideline 4)

to cause a pandemic.

- Develop procedures for diagnosis,

treatment and containment

(isolation)

of suspected cases and contacts

(see

Guideline 5)

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 6 of 31

WHO PANDEMIC PHASES

Location of

Specific action points

Action

event

(2009 revision)

(Country)

Phase 4 - Sustained Human to Human Transmission

Phase

4 is characterized by verified

Not affected

In addition to the above:

human-to-human transmission of an

- Monitor disease surveillance and

animal or human-animal influenza

guidance from affected countries and

reassortant

virus

able to cause

conduct local risk assessments

FM/HA

“community-level

outbreaks.”

The

- Reiterate guidance to minimise the

ability to cause

sustained disease

risk of exposure to novel influenza

outbreaks in a community marks a

strain and review infection control

significant upwards shift in the risk for a

procedures at workplace and clinics

pandemic. Any country that suspects or

(see Guideline 1 & 2 & 5)

has verified such an event should

- Consider implementing plans for

urgently consult with WHO so that the

FM/HA

situation can be jointly assessed and a

routine issue of antivirals for stand-by

treatment (see Section 3 and Guideline

decision made by the affected country if

implementation of a rapid pandemic

11)

containment operation is warranted.

- Review stocks of personal protective

Phase 4 indicates a significant increase in

equipment

(PPE) for medical staff,

FM/HA

risk of a pandemic but does not

respiratory cases, travellers; personal

necessarily mean that a pandemic is a

thermometers for

“self-monitoring”;

forgone conclusion.

and essential respiratory medications

(e.g. antibiotics) for treatment of cases

(see Guideline 4)

- Conduct pandemic preparedness

training for medical, first-aid, and

general staff

(incl. personal hygiene

and use of PPE)

Affected or

In addition to the above:

- Monitor for any travel restrictions

HoC/BU

travel/trade

imposed (see Guideline 6)

HM/HA

links

Review options for medical

All

evacuation (medevac) of cases out of

affected areas (see Guideline 4)

- If human to human transmission is

present

local

community,

implement actions for Phase 5 (below)

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 7 of 31

WHO PANDEMIC PHASES

Location of

Specific action points

Action

event

(2009 revision)

(Country)

Pandemic Phase 5-6 - Widespread Human Infection

Phase 5 is characterized by human-to-

Not affected

In addition to the above:

human spread of the virus into at least

- Consider implementing plans for

HoC/BU

two countries in one WHO region. While

accelerated issue of antivirals for

most countries will not be affected at this

stand-by treatment (see Section 3 and

stage, the declaration of Phase

5 is a

Guideline 11)

strong signal that a pandemic is imminent

Prepare to provide technical

and that the time to finalize the

assistance,

contingency

medical

organization,

communication,

and

staffing and supplies to assist affected

implementation of the planned mitigation

countries if needed

measures is short.

Affected or

In addition to the above:

- Heighten monitoring of reported

Note: Phase 5 active in April 2009

travel/trade

cases and disease surveillance

FM/HA

links

- Implement procedures for diagnosis,

treatment and containment (isolation)

HoC/BU

of suspected cases and contacts (see

Guideline 5)

- Consider relocation of dependants

expatriate staff, in line with the

Human Resource Policy Guidelines

FM/HA

- Review resources and capacity built

up in Phase 4 (above) and determine

need for external assistance and

additional supplies

FM/HA

- Develop contingency plans for

overload of clinics and replacement of

medical staff taking rest and

recuperation or falling ill

- Introduce

“self-monitoring” for

respiratory disease including routine

temperature checks (see Guideline 7)

All

- Avoid non-essential gatherings and

face-to-face meetings

(i.e. practice

“social distancing”)

- Monitor the development of a

pandemic influenza vaccine and

priorities for use

- If human-to-human transmission is

present

local

community,

implement actions for Phase 6 (below)

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 8 of 31

WHO PANDEMIC PHASES

Location of

Specific action points

Action

event

(2009 revision)

(Country)

Phase

6, the pandemic phase, is

Any affected

In addition to the above:

characterized by community level

or not yet

- Implement full scale measures outlined

HoC/BU

outbreaks in at least one other country

affected

in Phase 5 (above)

FM/HA

in a different WHO region in addition

- Issue antivirals to new staff

(not in

to the criteria defined in Phase

receipt

previously)

for

stand-by

Designation of this phase will indicate

treatment

that a global pandemic is under way.

- Draw on contingency plans for clinic

FM/HM

overload,

medical support staff,

pharmaceutical and other medical

supplies as necessary

HoC/BU

- Prepare to use alternate

(non-health

care) facilities to care for ill staff if

necessary

Strengthen employee assistance

programmes (EAPs) and other means to

provide social/psychological support for

staff and dependants

- Monitor for antiviral resistance and

update guidance on use of available

medications

- Provide guidance on the availability

and use of pandemic influenza vaccines

(when available)

Post-peak Period - Possibility of Recurrent Events

During

the post-peak

period,

Any affected

An intensive phase of recovery and

pandemic

disease levels in most

or not yet

evaluation may be required in the post-

countries with adequate surveillance

affected

peak period:

will have dropped below peak observed

- Review effectiveness of treatments and

levels. The post-peak period signifies

HoC/BU

countermeasures

that pandemic activity appears to be

HM/HA

- Update guidelines and procedures

decreasing; however, it is uncertain if

HM/HA

- Restock essential medicines and

additional waves will occur and

HA/HM

countries will need to be prepared for a

supplies

second wave.

- Assess vaccine coverage and update

guidelines for further use

- Monitor disease surveillance data and

Previous pandemics have been

characterized by waves of activity

be prepared for additional waves

spread over months. Once the level of

disease activity drops, a critical

communications task will be to balance

this information with the possibility of

another wave. Pandemic waves can be

separated by months and an immediate

“at-ease” signal may be premature.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 9 of 31

WHO PANDEMIC PHASES

Location of

Specific action points

Action

event

(2009 revision)

(Country)

Post Pandemic Period - Disease Activity at Seasonal Levels

In the post-pandemic period, influenza

Any affected

An intensive phase of recovery and

disease activity will have returned to

or not yet

evaluation may be required at the end of

levels normally seen for seasonal

affected

a pandemic or between waves:

influenza. It is expected that the

- Review effectiveness of treatments

pandemic virus will behave as a

HoC/BU

and countermeasures

seasonal influenza A virus. At this

HM/HA

- Update guidelines and procedures

stage, it is important to maintain

- Restock essential medicines and

surveillance and update pandemic

preparedness and response plans

supplies

accordingly. An intensive phase of

- Assess vaccine coverage and update

recovery and evaluation may be

guidelines for further use

required.

Section 2 Containment Measures to Reduce Risk of Influenza Transmission

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 10 of 31

For persons living or travelling within an affected country, the following table outlines specific measures to be

considered by Head-of- Country/Business Unit Manager (HoC/BU), Facilities Manager (FM), Health

Adviser(HM)/Health Manager (HA) and Individual (ID) for each pandemic phase.

“Affected” means countries where the “novel” influenza virus subtype is present in animals (as per WHO).

Measures

Action by

Comments

Phase 3

Phase 4

Phase 5

Phase 6

General information on risk avoidance and

Yes

personal hygiene

Human Cases infected (or suspected) with

the “novel” influenza virus

Yes

Plan to

- Confinement (isolation) as appropriate to

accommodate

Yes

local situation

potentially large

Yes

number of severe

- Surgical face masks for cases

Yes

cases.

- Surgical face masks for persons with

respiratory illness attending clinics

- Appropriate PPE for health care staff in

clinics (including training on use) - see

Guideline 4

Contacts of cases

- Tracing and follow-up of contacts

Yes

Not feasible once

pandemic starts.

- Voluntary quarantine (home

Yes

confinement) and health monitoring

Yes

- Surgical face masks if in close contact (<

Reserve

Yes

1 metre or 3 feet) with others

antivirals for

early treatment

- Refer contacts for medical advice on

once pandemic

short-term prophylaxis (preventive

starts.

treatment) with antivirals

Staff and dependants in affected areas

- Self-health monitoring (incl. temp. check)

Yes

Seek early

and reporting of illness

treatment.

Yes

- Voluntary home confinement (do not

Take hygiene

attend work/school) if respiratory

measures to

Consider

Yes

symptoms develop

reduce risk to

Consider

Yes

household

- Avoid public gatherings, functions and

members.

non-essential meetings

Consider early if

- Avoid attendance at pre-school, school,

local clusters.

university

Yes

Follow local

- Wear face-masks in public places

recommendation

- Wear face-masks in public places if

Not known to be

respiratory symptoms (suggestive of

effective in

“novel” influenza virus) develop

preventing

infection.

Should be worn

in public and at

clinics to reduce

transmission to

others.

Workplaces in affected areas

- Promote personal hygiene (hand

Yes

washing) and frequent disinfection of

potentially contaminated surfaces

Yes

- Appropriate PPE for responders to cases

in the workplace, and for cleaning and

Yes

Workplace

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 11 of 31

catering staff (including training on use) -

temperature

see Guideline 4

checks (incl.

thermal

- Promote self-health monitoring

N/A

scanning) is not

recommended.

- Widespread environmental/air

disinfection

Travel to affected areas (where clusters

are occurring) within a country

Yes

- Avoid contact with live pigs, birds and

Yes

If affected areas

poultry

remain localised.

- Defer non-essential travel to and from

locally affected area

Visitors to and from affected areas

- Visitors with respiratory illness should

Yes

postpone travel

Yes

Information

- General information on outbreak, risk

relevant to

avoidance, personal hygiene and medical

Phase.

Yes

support

Yes

- Avoid contact with live poultry and

infected poultry farms

Yes

Seek early

- Self-health monitoring (incl. temp. check)

treatment.

and reporting of illness

HoC/BU

Yes

Take hygiene

- Voluntary hotel confinement and do not

measures to

attend work if respiratory symptoms

reduce risk to

develop

hotel members.

- Obtain medical advice on use of

Antivirals may

antivirals (for standby treatment and short-

be reserved for

term prophylaxis) during and after travel

early treatment

out of country

(c.f. prophylaxis)

once pandemic

starts.

Staff and dependants leaving affected

countries

Yes

- Staff with respiratory illness should

HoC/BU

Yes

Antivirals may

postpone travel

be reserved for

- Obtain medical advice on use of

early treatment

antivirals (for standby treatment and short-

(c.f. prophylaxis)

term prophylaxis) during and after travel

once pandemic

out of country

starts.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 12 of 31

2.0

Medical Supplies

2.1

General Medical Supplies

Individual operating units and responsible medical personnel should consider availability of general medical

supplies and stocks of general drugs and medical supplies (including consumables such as syringes, needles,

etc.) for use during a pandemic.

Antivirals

Antiviral drugs for influenza are now an important adjunct to vaccination for the treatment and prevention of

influenza. However, they are not a substitute for vaccination. When taken before infection or during the early

stage of the disease (within two days of illness onset), antivirals may help prevent infection, and if infection has

already taken hold, their early administration may reduce the duration and severity of illness.

A new class of antivirals, the neuraminidase inhibitors, has been developed which include Oseltamivir

(Tamiflu®) and Zanamivir (Relenza®). These drugs have few adverse side-effects and have shown little

resistance to the virus to date. However, they are currently not widely available for use in many countries.

Other antivirals could potentially have some effectiveness against a new emerging strain of influenza and may

have some use in the health care setting.

Antibiotics

As influenza is often complicated by secondary bacterial infection of the lungs, antibiotics could be life saving

in the case of late-onset pneumonia. Availability and stocks of antibiotics targeted to pulmonary bacterial

infection (such as a fluroquinolone, co-trimoxasole, vancomycin, cephalopsporin, etc) should be assessed.

Note: Antivirals and antibiotics are prescription only medications and purchases must be arranged in

consultation with a BP Az SPU Occupational Health adviser.

Antipyretics

Antipyretic such as paracetamol will be indicated as in most febrile diseases to relieve pain and control fever.

Aspirin is contraindicated in those suspected of having influenza. Antipyretics are generally widely available but

potential use and stocks should be assessed.

2.2

Indicators for Issue of Antivirals to Employees

The accountability for issue of antivirals to employees rests with the Head-of-Country (or delegate) subject to

the Crisis & Continuity Management Team, Regional Health Directors & VP Health confirming a change in risk

due to a “novel” influenza virus sufficient to initiate the issue of antivirals from the Company stockpile.



Antiviral will not be issued to employees until there is a perceived or actual increase in the level of

pandemic risk which is supported by the RGVP, HoC and Health Director and/or as advised by the

WHO or National Alert Authority.



The level of risk to countries will be continuously monitored and informed via the Crisis Management

Network.



Once the trigger for issue is confirmed, an emergency approach to prescribing and dispensing may be

required in high risk, imminently affected countries to ensure the timely delivery.

Note: This guidance does not apply to antiviral stocks required to meet operational needs e.g. where the

Company operates clinics or provides medical care.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 13 of 31

Before a decision to issue antivirals to staff is made, the Head-of-Country should seek guidance from the Regional

Health Director on interpreting the global and country indicators outlined below.

Global Indicators

The WHO Phases are escalated on the basis of fixed criteria relating more to geographical spread than severity. An

increase in clusters of cases in a number of countries may lead to Phase escalation but this does not translate

immediately to heightened risk in every country. Country response should not be fixed to WHO Phase changes but

based on appropriate consultation and assessment.

Routine (non-urgent) issue of antivirals will be considered after the declaration of WHO Phase 4 or above.

Accelerated (urgent) issue of antivirals will be considered after the declaration of WHO Phase 5 or above.

Country Indicators

A country risk assessment should be initiated in conjunction with the Country medical adviser/s, the Regional Health

Director and the VP Health to consider additional factors including:



the confirmed presence of human

“novel” influenza cases in the country according to the

WHO/CDC(US) criteria for case definition.



the confirmed presence of human “novel” influenza cases in a neighbouring country and countries with

frequent travel and trade links



the number of such cases and the rate of escalation



the number of cases likely to be imported from outside the country



the number of cases likely resulting from sustained human-to-human transmission in the country



the proximity of cases to local communities and sites



the available evidence concerning the severity of the “novel” influenza (self-limiting, response to

treatment, sensitivity to antivirals, fatalities etc.)



the available evidence on the outbreak from the WHO and CDC investigation team, the local Health

Department/s and other relevant authorities



actions taken by governments and local health authorities e.g. deployment of Strategic National

Stockpiles of antivirals etc.



the capabilities of the local medical infra-structure for diagnosis and treatment and the availability of

antivirals from local clinics

 the expected time taken to complete the issue of antivirals to staff

 the actions taken in other perceived higher risk countries

 the actions taken by other companies or local authorities in the same country or area

 the possible communication issues associated with this action including:

o the anticipated reaction of staff

o acceptance by local health authorities

o media response and public sympathy

 other potential consequences such as:

o the potential for side-effects in relation to the expected severity of the influenza

o the potential for inappropriate use and the emergence of drug resistance

the depletion of the stockpile and reduced capacity to mitigate later, and possibly

more severe, “waves” of influenza

2.3

Principles Governing Issue of Antivirals to Employees

 Primary responsibility for health care management in the event of an Influenza Pandemic

remains with Governments and established health care providers.

 Where BP provides health care services, it will continue to provide medical support during a

pandemic (including the provision of antivirals).

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 14 of 31

 In addition to this, BP will endeavour to supply antivirals to all employees when the pandemic

risk increases to supplement limited supplies.

 To allow for uncertainty of dose and duration of treatment of a novel pandemic virus and other

contingencies, more than one standard treatment course may be provided for each employee.

 Antivirals will only be issued to BP employees and contractor staff occupying roles that would

normally be performed by BP employees as defined in the HR Pandemic policy.

 Antivirals will not be issued to employees until there is a perceived or actual increase in the

level of pandemic risk which is supported by WHO advice.

 The level of risk to countries will be continuously monitored and informed via the Crisis

Management Network.

 The accountability for issue of antivirals will be the Head-of-Country (or delegate) subject to

Group Crisis Team confirming a change in risk sufficient to initiate the issue to employees (see

Guideline 11).

 Once the indication for issue is confirmed, an emergency approach to prescribing and dispensing

may be required in high risk, imminently affected countries to ensure the timely delivery.

2.4

Tamiflu® Dispensing Plan

In preparation for any local outbreak or pandemic situation, specific plans for sub-distribution and dispensing of

Tamiflu® should be prepared in conjunction with locally registered medical practitioners (and pharmacists, if

necessary).

As a prescription drug, Tamiflu® will only be issued by BP under medical supervision and in specific

circumstances including:

 Emergency treatment of symptoms in the event that employees cannot access local supplies.

 Standby treatment for employees travelling to remote or high risk locations or other situations

where BP judges that employees should have ready access to Tamiflu® (such as a perceived or

actual increase in the level of pandemic risk which is supported by WHO advice.

 Targetted, short-term prophylaxis

(for

10days) to certain individuals for the purpose of

containing or reducing transmission of the virus early in an outbreak.

Note: As stated above, public health interventions (including early detection and containment) will be

the principal means of control during a widespread pandemic. Because of anticipated limited supplies

of antivirals during a pandemic situation, it will not be feasible or recommended to administer

Tamiflu® to large numbers of well people for long-term (6 weeks) prophylaxis (i.e. prevention of

influenza).

The Tamiflu® Dispensing Plan is outlined below:

This contains the specific recommended action points for each of the WHO Pandemic Phases referred to in the

WHO Global Influenza Preparedness Plan (2009) in planning for potential dispensing of Tamiflu®. These

Sections also indicate who is accountable for each action including:

 Head-of-Country (abbreviated as “HoC”)

 Facilities Manager (abbreviated as “FM”)

 Health Manager/Health Adviser (abbreviated as “HM/HA”)

 Individual (abbreviated as “ID”)

In planning for dispensing of Tamiflu® reference should also be made to:

 Guideline 9 - Principles Governing Issue of Antivirals to Employees

 Guideline 10 - Prescribing & Dispensing Antivirals to Employees

 Guideline 11 - Indicators for Issue of Antivirals to Employees

For each influenza pandemic phase, as declared by WHO, the table outlines specific measures to be actioned by

Head-of-Country (HoC), Facilities Manager (FM), Health Adviser (HA) and Individual (abbreviated as

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 15 of 31

“ID”) in preparation for dispensing of Tamiflu ®.

“Affected” means countries where the “novel” influenza

virus subtype is present in animals (as per WHO).

WHO PANDEMIC PHASES

Location of

Specific action points

Action

event

(2009 revision)

(Country)

Phase 1-3 - Predominantly Animal Infections: Few Human Infections

In Phase

1 no viruses circulating among

Any affected

- No specific action

animals have been reported to cause infections

or not yet

in humans.

affected

In Phase 2 an animal influenza virus circulating

Any affected

- Assess availability of Tamiflu® and other

among domesticated or wild animals is known

or not yet

antivirals and priorities for supply

to have caused infection in humans, and is

affected

therefore considered a potential pandemic

threat.

In Phase

3 an animal or human-animal

Not affected

In addition to the above:

influenza reassortant virus has caused sporadic

- Nominate a locally registered medical

cases or small clusters of disease in people, but

practitioner to provide professional oversight for

has not resulted in human-to-human

procurement and dispensing

HM/HA

transmission sufficient to sustain community-

- Procure stocks of Tamiflu® and ensure secure

level outbreaks. Limited human-to-human

storage and handling and inventory control

transmission

may occur under some

circumstances, for example, when there is close

- Prepare and maintain detailed staff listings for

each location

contact between an infected person and an

unprotected caregiver. However, limited

- Develop emergency Tamiflu® dispensing

transmission

under

such

restricted

protocols for treatment of unexpected cases of

circumstances does not indicate that the virus

animal Influenza (“novel virus”)

has gained the level of transmissibility among

- Develop Tamiflu® prescribing and dispensing

humans necessary to cause a pandemic.

plans with provision for both routine and

accelerated issue for stand-by treatment

(and

short-term prophylaxis) of Pandemic Influenza

(see Guideline 9 & 10)

- Develop information/briefing packs for staff

Affected or

In addition to the above:

- Deploy stocks of Tamiflu® to strategic

HM/HA

travel/trade

locations and ensure secure storage and handling

links

WHO PANDEMIC PHASES

Location of event

Specific action points

Action

(Country)

(2009 revision)

Phase 4 - Sustained Human to Human Transmission

Phase

4 is characterized by verified

Any affected or

In addition to the above:

human-to-human transmission of an

not yet affected

- Monitor disease surveillance and guidance

HA/HM

animal or human-animal influenza

from affected countries and conduct local risk

reassortant

virus

able to cause

assessments

HM/HA

“community-level

outbreaks.”

The

- Review Tamiflu® stocks in strategic locations

ability to cause

sustained disease

- Assess quantities required for prophylaxis,

outbreaks in a community marks a

significant upwards shift in the risk for a

emergency treatment and stand-by treatment of

Pandemic Influenza at sites

HoC/HM

pandemic. Any country that suspects or

has verified such an event should

- Consider implementing dispensing plans for

urgently consult with WHO so that the

routine issue of Tamiflu® for stand-by

situation can be jointly assessed and a

treatment (see Guideline 11)

decision made by the affected country if

- Maintain personal supply of Tamiflu® in a

HoC

implementation of a rapid pandemic

safe location and become familiar with

containment operation is warranted.

instructions for use

Phase 4 indicates a significant increase in

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 16 of 31

risk of a pandemic but does not

- If human-to-human transmission is present in

necessarily mean that a pandemic is a

the local community, implement actions for

forgone conclusion.

Phase 5 (below)

Pandemic Phase 5-6 - Widespread Human Infection

Phase 5 is characterized by human-to-

Any affected or

- Consider implementing dispensing plans for

All

human spread of the virus into at least

not yet affected

accelerated issue of Tamiflu® for stand-by

two countries in one WHO region. While

treatment (see Guideline 11)

most countries will not be affected at this

stage, the declaration of Phase

5 is a

strong signal that a pandemic is

imminent and that the time to finalize the

organization,

communication,

and

implementation of the planned mitigation

measures is short.

Note: Phase 5 active in April 2009

Phase

6, the pandemic phase, is

Any affected or

In addition to the above:

characterized by community level

not yet affected

- Issue Tamiflu® to new staff (not in receipt

outbreaks in at least one other country in

previously) for stand-by treatment

a different WHO region in addition to the

criteria defined in Phase 5. Designation

of this phase will indicate that a global

pandemic is under way.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 17 of 31

WHO PANDEMIC PHASES

Location of

Specific action points

Action by

event (Country)

(2009 revision)

Post-peak Period - Possibility of Recurrent Events

During the post-peak period, pandemic

Any affected or

An intensive phase of recovery and evaluation

disease levels in most countries with

not yet affected

may be required in the post-peak period:

adequate surveillance will have dropped

- Review records for usage, efficacy and

below peak observed levels. The post-peak

adverse side-effects

period signifies that pandemic activity

HM/HA

- Restock essential antiviral supplies

appears to be decreasing; however, it is

uncertain if additional waves will occur

- Be prepared to dispense for additional waves

and countries will need to be prepared for

a second wave.

pandemics

have

been

characterized by waves of activity spread

over months. Once the level of disease

activity drops, a critical communications

task will be to balance this information

with the possibility of another wave.

Pandemic waves can be separated by

months and an immediate “at-ease” signal

may be premature.

Post Pandemic Period - Disease Activity at Seasonal Levels

In the post-pandemic period, influenza

Any affected or

An intensive phase of recovery and evaluation

disease activity will have returned to levels

not yet affected

may be required at the end of a pandemic or

normally seen for seasonal influenza. It is

between waves:

expected that the pandemic virus will

- Review records for usage, efficacy and

behave as a seasonal influenza A virus. At

adverse side-effects

this stage, it is important to maintain

surveillance

and update pandemic

preparedness

and

response

plans

accordingly. An intensive phase of

recovery and evaluation may be required.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date: 2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN BE

FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 18 of 31

2.5

Tamiflu® Stocks

Primary responsibility for health care management in the event of an Influenza Pandemic remains with

Governments and established health care providers.

In circumstances where Governments may not be able to fully provide appropriate health care

management, BP will endeavor to facilitate the provision of additional health care support through its

internal health care services to employees and dependants including:

 assisting with access to the full level of local health services and provisions;

 providing additional medical support, prioritizing those at greatest risk;

 making every effort to facilitate medical support for individuals on assignment out of their

home country in line with BP Expatriate policy.

If a pandemic is declared it is likely that stocks of medicine useful against influenza, particularly

Tamiflu®, would be rapidly consumed. This is particularly the case in countries where resources are

limited and other health care priorities preclude stockpiling of antivirals.

Therefore it is recommended that BP Az SPU Heads-of-Country/Business Unit Leaders, in conjunction

with BP Az SPU Health advisers, assess the local availability of Tamiflu® and priorities for supply.

This is particularly important in areas where public health and medical services are limited. An

assessment of need should take account of factors such as:

 proximity to probable influenza outbreak location/s;

 the robustness of local public health infrastructure to contain and limit an outbreak;

 the robustness of local medical facilities to provide necessary treatment;

 logistics for medical evacuation (medevac) and “shelter-in-place” (if medivac is not possible);

 the current level of BP preparedness

(including availability of antivirals, other medical

supplies, potential vaccines);

 any other country specific health risks; etc.

 the epidemiology of previous pandemics, the likely attack rate etc.

Wherever possible, BP Az SPU will endeavour to facilitate the provision of additional supplies of

Tamiflu® to employees through its health care services.

Tamiflu® is a prescription only medication and the cost varies considerably depending on whether it is

ordered directly from the manufacturer, from a pharmacy or from a clinic. Therefore, purchases should

follow normal BP procurement practices and must be arranged with Head-of-Country approval and

in consultation with Health Manager.

Stocks of Tamiflu® should be under the responsibility of a BP (or BP nominated) medical adviser

at all times. Subject to local legislative requirements, a designated BP person may hold Tamiflu®

stocks on behalf of a doctor who will be responsible for procurement and providing advice on

dispensing and treatment.

Storage of Antivirals - Supplies should be kept in a secure place and stored at 25^oC (77^oF) within the

range 15 - 30^oC (59 - 86^oF) (Ref:http://www.rocheusa.com/products/tamiflu/pi.pdf )

The current shelf-life for Tamiflu® capsules is around 5 years and Tamiflu® paediatric suspension is 2

years.

According to the latest recommendations of European Medicines Agency and in view of the recent

outbreak of the novel influenza A/H1N1 virus, the European Medicines Agency has also reviewed

ways to use Tamiflu capsules in case of a shortage. The shelf-life for Tamiflu® paediatric suspension

is 2 years.capsules the shelf-life for Tamiflu was around 5 years however the Agency’s Committee for

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 19 of 31

Medicinal Products for Human Use (CHMP) recommended that Tamiflu capsules that are already on

the market may be used for up to two more years after their current five-year expiry date during a

declared pandemic.

EMEA - extension

2.6

Tamiflu® Sub-Distribution

2.6.1 AzSPU Antivirals Distribution Procedures

Storage and Sub-distribution of Antivirals:



Antivirals will initially be supplied to a nominated secure country site. Storage is to be in

accordance with the Storage and Handling Guidelines.



Sub-distribution of antivirals to sites within the country is recommended to facilitate rapid

issue to employees whilst minimizing the possibility of sequestration. This will be based on a

country risk assessment and subject to Regional, HoC, Security and Medical endorsement.

Regional SPA’s and HoC’s should prepare detailed listings of the employees for each proposed

distribution site.

BP Az SPU Tamiflu® stocks should initially be supplied to a nominated secure country site. Storage is

to be in accordance with any local legislative requirements and the guidelines on storage and handling

available from the product distributor or manufacturer.

Sub-distribution of antivirals to sites within the country is recommended to facilitate rapid issue to

employees whilst minimizing the possibility of sequestration. This will be based on a country risk

assessment and subject to Head-of-Country and Health Manager’s endorsement. Guidance is provided

in the Tamiflu® Dispensing Plan below.

To prepare for potential dispensing to individuals, HA should ensure that detailed listings of the

employees are prepared and maintained for each proposed distribution site.

2.7

Prescribing & Dispensing Antivirals to Employees



Local laws and regulations for prescription and dispensing necessitate a country-by-country

approach to the issuing of antivirals.



Where BP operates clinics for employees to access medical treatment, HM are to ensure that

supplies of antivirals are available for treatment.



HM, in conjunction with locally registered medical practitioners and supported by BP Az SPU

Health advisers, are required to prepare a country plan for prescribing and dispensing

antivirals.

The plan should include the provision for both routine

(non-urgent) and

accelerated (urgent) prescribing and dispensing of antivirals to all employees (see below):

Routine (Non-Urgent) Issue of Antivirals

The plan for issue of antivirals to employees should be based on the usual practice for prescribing and

dispensing of “prescription only” medicines, and be fully compliant with local laws and regulations in

the relevant country or countries.

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 20 of 31

The dispensing plan should be prepared under the supervision of a locally registered medical

practitioner(s), and with BP medical guidance. To comply with professional standards of practice:



Antivirals should only be dispensed to employees once a prescription has been written

following individual or group consultations (dependent on local regulatory requirements).



Where practicable, prescribing authority may be delegated to another suitably trained health

professional, authorised to act on the practitioners behalf.



Reasonable steps should be taken by the prescribing doctor to ensure that all persons who are

offered antivirals:

- have no medical contraindications to prescribing;

- are made aware of its appropriate use, potential adverse side-effects and actions to take if

they should occur;

- are advised to seek the medical opinion of a “treating” physician before taking antivirals;

- are issued with instructions for self-treatment to be followed as a last resort in the event of

an unreasonable delay between the dispensing of antivirals, and their administration.



Any person(s) with concern(s) should be offered a face-to-face consultation with a medical

practitioner before a prescription is issued.



At the point of issue of antivirals, employees should be given written advice on the

appropriate use of antivirals and informed of other actions they can take to protect themselves

and their families.



The plan should include a system for detailed recording of the issue of antivirals to employees

and other record keeping requirements as advised by the responsible doctor.

Accelerated (Urgent) Issue of Antivirals

The plan for routine issue should continue to be implemented - but accelerated as fast as reasonably

practicable - to ensure the timely delivery in the face of a rapidly increasing pandemic risk.

This may be achieved by:

- allocating additional resources;

- engaging more clinics;

- offering group consultations;

- Implementing e-dispensing; etc.

If regulations are relaxed, such as re-scheduling of antivirals as an over-the-counter (OTC) drug, more

rapid acceleration may be possible(dispensing if regulations are relaxed (e.g. to allow over the counter

dispensing by a pharmacist)

Local regulations may not explicitly provide for emergency dispensing.

2.8

Use of Antiviral Medication

Antivirals for Use against Influenza

When taken before infection or during the early stage of the disease (within two days of illness onset),

antivirals may help prevent infection, and if infection has already taken hold, their early administration

may reduce the duration and severity of illness.

A new class of antivirals, the neuraminidase inhibitors

(including Oseltamivir

(Tamiflu®) and

Zanamivir (Relenza®), have few adverse side-effects and have shown little resistance to the virus to

date. A summary of the potential use and features of the two currently available neuraminidase

inhibitors is contained in the table below:

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 21 of 31

Tamiflu®

Relenza®

(Oseltamivir)

(Zanamivir)

Treatment

Adults and children >1 year

Adults and children >7 years

Prophylaxis

Adults and children (above 1 year of age)

Not approved for prophylaxis in

many

countries

Administration

Capsule (and suspension) for oral

Powder for inhalation

Side-effects

Few, minor gastro-intestinal

Bronchospasm

(> 33 million treatments to date)

Shelf-life

5 years

3 years

(2 years for oral suspension)

Storage

At 25^oC (77^oF)

< 25^oC (77^oF)

Range 15 - 30^oC (59 - 86^oF)

Resistance

< 0.4%

Low (not fully tested)

Market

97%

Other antivirals could potentially have some effectiveness against a new emerging strain of influenza

and may have some use in the health care setting.

The antiviral most likely to be of value in an influenza pandemic is Oseltamivir (know by its tradename

Tamiflu®) which can be taken orally in capsules or paediatric oral suspension (12mg/ml).

2.8.1 Use of Tamiflu®

The complete product information for doctors prescribing Tamiflu®, and a patient information

sheet, are available at the following websites:

Complete prescribing information: http://www.rocheusa.com/products/tamiflu/pi.pdf

Information for health care professionals: http://www.tamiflu.com/hcp/default.aspx

Note: The local pharmacopeia and these sites should be consulted for the most up-to-date prescribing

and product information.

The following brief notes outline the potential use of Tamiflu® during a pandemic. It assumes that the

influenza strain is associated with a high rate of serious illness, in which case, two main situations may

require using Tamiflu®:

1. Treatment with Tamiflu®

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 22 of 31

Tamiflu® is a prescription medication approved for the treatment of uncomplicated acute Influenza

(types A and B) in patients over the age of 1 year.

(It is not suitable for patients under the age of 1

year).

During a pandemic, Tamiflu® should only be issued under medical supervision and in specific

circumstances including:

 Treatment of influenza symptoms in the event that employees cannot access supplies

through the local health care system;

 Standby treatment for employees working in (or travelling to) high risk locations or

other situations where BP judges that employees should have ready access to antivirals

(based on a perceived or actual increase in the level of pandemic risk which is supported

by WHO advice.

Note: For the treatment to be effective it must be started as early as possible after the onset of

symptoms and certainly within 48 hours.

Typical symptoms are summarised below:

Symptoms of Influenza

 Abrupt onset of fever above 38 ^oC /100 ^oF

Plus any of the following:-

 Non-productive cough and; either travel to a

 Malaise (Fatigue)

country with an influenza outbreak, or contact

 Chills (Rigors)

history with an infected person, or a positive rapid

 Headache

test kit result (if available)

 Myalgia (Muscle pains)

 Sore throat

(Running nose, nausea, vomiting and

diarrhoea are more common in

children than in adults)

CDC (US) & WHO case definitions for human infections with influenza A (including H1N1,

H5N1) are contained in Guideline 8. However, during an influenza pandemic situation, anyone with a

fever, cough and symptoms outlined above may be presumed to have influenza and may be

recommended to commence treatment immediately.

Tamiflu® is available in capsules (75mg & 30 mg) and as a paediatric suspension (12mg/ml) for oral

administration.

Note: If a paediatric suspension is not available, instructions for Emergency Compounding of an

Oral Suspension from Tamiflu® Capsules (final concentration 15mg/ml) and the relevant paediatric

dose

regime

available

the

prescribing

information

at:

http://www.rocheusa.com/products/tamiflu/pi.pdf

2. Prophylaxis with Tamiflu®

During a widespread pandemic, public health interventions (including early detection and containment)

will be the principal means of control. Because of anticipated limited supplies of antivirals during a

pandemic situation, it will not be feasible or recommended to administer Tamiflu® to large numbers of

well people for long-term prophylaxis (i.e. preventive treatment of influenza).

During a pandemic, Tamiflu® should be reserved for treatment of people who are ill, rather than

prophylaxis (prevention) in well people. However, Tamiflu® can potentially protect from, or reduce

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 23 of 31

severity and duration of the disease in those exposed to influenza cases. Therefore, it may be

recommended for short-term, targetted prophylaxis in specific circumstances. Such situations may

include:

 Post-exposure: At an early stage, when isolated cases or small outbreaks are occurring,

Tamiflu® can be given to persons known to have been in close and unprotected contact with

suspected or probable influenza cases.* For maximum effect, the drug needs to be started as

soon as possible and within 48 hours of exposure to infection.

*Note: In this context, a close contact is defined as an intimate contact (< 1 metre), providing

care, in the same household, having direct contact with respiratory secretions (saliva droplets

of a suspected case, coughing or sneezing), body fluids and/or excretions of highly suspected

or probable cases (see Guideline 5).

 Pre-exposure: BP staff who will be repeatedly exposed to a suspected or probable influenza

cases (e.g. health care staff, essential services field staff working in close proximity with

human or animal cases) could potentially be offered protection with Tamiflu®.* (Prophylaxis

may continue for a maximum of 6 weeks, including one week after the last known exposure).

*Note: Even where supplies of Tamiflu® are sufficient, pre-exposure prophylaxis would be

limited to high-risk exposure during official duty.

 Prophylaxis in international travellers. To limit and slow down international spread, BP

will make recommendations for international travel, should an influenza pandemic be

declared. BP travellers should follow these recommendations when they are issued.

Below is the AzSPU anti-virals stocks :

number of treatment courses

Location

first shipment

second shipment

total

Central Azeri (CA) platform

200

220

West-Azeri (WA) platform

200

220

Chirag platform

140

160

Shah Deniz (SD) platform

130

150

East Azeri (EA) platform

200

220

Istiglal

tbc

Dada-Gorgud

tbc

Sangachal Terminal

580

600

Ganja MediClub clinic

100

BP Baku In House OH clinic

15127

Baku MediClub Clinic

180

320

500

Baku ISOS Clinic

160

340

500

Tbilisi MediClub Clinic

450

612

1062

Supsa Terminal

110

160

PSG1

100

PSG2

100

Akhaltsekhi

160

Bakuriani hotel clinic

Total

1000

18480

19480

available in stock for Az and Geo

19480

2.9

Personal protective equipment (PPE)

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 24 of 31

Personal protective equipment (PPE) is primarily for medical staff, first-aid attendants, responders

to suspected cases, and cleaning/catering staff trained how to use it, but it may also be recommended

for other situations outlined below.

Use of Masks to Control Influenza Transmission

The effectiveness of masks in preventing influenza transmission remains uncertain and the widespread

use of masks in the community is not generally recommended. Individuals can shed influenza virus for

1 day before symptoms appear. Therefore masks may not effectively limit transmission in the general

community. Instead, the emphasis should be placed on respiratory hygiene/cough etiquette at home, at

work, and in other public settings (see Guideline 2).

However, wearing a properly fitted procedure mask (i.e with ear loops), surgical mask (i.e. with ties)

or an N95 respirator (for those trained in its use) may offer some protection from respiratory droplets

from an infected person in close proximity (within 1 meter or 3 feet). Also masks may also help limit

the potential for an infected person to contaminate nearby surfaces and objects.

Procedure mask (with ear loops) Surgical mask (with ties)

N95 disposable respirator

Proper selection and training on use (including donning, checking fit, removal and disposal) is

necessary to ensure the effectiveness of any mask or respirator.

The following recommendations focus on the appropriate use of masks in conjunction with other

influenza control strategies in the workplace:

 Health-care Personnel

- An N95 or equivalent mask should be worn by health-care

personnel (including first-aiders and responders to influenza cases in the workplace) who

may be in close contact (i.e., within 1 meter or 3 feet) with a person who has symptoms of a

respiratory infection, particularly if fever is present

 Suspected Influenza Cases - A surgical or procedure mask should be provided to staff who

are coughing or have other symptoms of a respiratory infection in the workplace. The mask

should be worn until the person leaves the workplace and has received medical advice.

Persons who arrive at a clinic with respiratory symptoms should also be given a surgical mask

on arrival. The mask should be worn until the person leaves the clinic. Persons who are

diagnosed with influenza by a doctor should remain isolated until the illness has resolved

and they have been cleared by a doctor. They should wear a mask when they can’t avoid

close contact with other persons.

 Contacts of Suspected or Confirmed Cases - Contacts of suspected or confirmed cases of

influenza should also wear a surgical or procedure mask, as they may be infectious for 1 day

before symptoms develop. Contacts should remain at home for 7 days (i.e. until they are

well outside the incubation period for influenza - typically 1-4 days but may be longer for a

new virus). They should wear a mask when they can’t avoid close contact with other persons.

 Cleaning and Catering Staff - Staff who are required to clean potentially contaminated

surfaces should wear a surgical or procedure mask and other appropriate PPE. Also, if a

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 25 of 31

person from cleaning or catering staff becomes ill, they may have the potential to cause

widespread transmission and contamination depending on the nature of their duties. To

minimize the potential impact on the facility if such a person becomes ill at work, it may be

recommended that these personnel wear disposable surgical or procedure masks (and gloves)

while carrying out their duties during a pandemic outbreak as an additional precautionary

measure. If the person becomes ill, but has been wearing a mask and gloves for at least 1 day

before the onset of symptoms, then it may not be necessary to designate all staff in the

relevant service area as close contacts

 General Staff - Staff should be encouraged to purchase their own supplies of surgical or

procedure masks for personal use should they develop influenza symptoms, so as to minimize

the risk of spreading the virus to others. Also, some individuals may choose to wear a mask

for additional protection for short periods in enclosed, crowded and poorly ventilated

environments such as public transport.

Supply of Personal Protective Equipment (PPE)

Staff providing medical care, and other staff who may be exposed to cases during the course of their

work, or required to clean potentially contaminated surfaces, should be supplied with other appropriate

PPE. In addition to supply, staff must be properly trained in its use.

In the event of a pandemic it is anticipated that masks and other PPE will be in short supply. It is

recommended that offices and operating units assess potential need

(for clinics, for use in the

workplace and for personal use) and determine the stocks required to be able to respond to the

demand.

Supply of PPE is dependent on local specificities, regulation and the availability of quality suppliers

and there will be no central procurement activity or funding. Each Head-of-Country (HoC) and local

businesses, should conduct a local assessment (in conjunction with HM) to identify the items required

and estimate the potential numbers to be supplied. The table below should be used for guidance

purposes only as local requirements will vary.

Control Tier:

<<2>>

Revision Date: 25 September

2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT

CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 26 of 31

Type of PPE

Number of items for each person in the respective Staff Group at the Facility (*)

Clinic Use

Workplace Use

Personal Use

Health-care

Suspected

First-aiders

Suspected

Cleaning

General Staff

Staff involved

Influenza

and

“Self-purchase”

Clinical

Cases

Responders

Cases

Catering

(**)

Treatment

arriving at

to Influenza

appearing

Staff

the Clinic

Cases in the

Work

Workplace

Procedure mask

150

(with ear loops)

or Surgical mask

(with ties)

N95 disposable

500

respirators

Safety goggles or

face-shield

Surgical gloves

500

(latex)

Disposable

500

150

gloves (plastic)

Aprons

500

150

(disposable)

Surgical gowns

500

(disposable)

Head covers

500

Shoe

covers

500

(pair)

Alcohol hand-

500

100

rub disinfectant

(disposable

hand-wipes)

Biohazard bag

500

(large, small)

*Note: These numbers are for guidance purposes only - a local assessment should be done to estimate the potential

need in each workplace. In the face of a full-blown pandemic, it is likely that non-critical operations will shut-down

and therefore the need for PPE will be expected to be less than for critical operations.

**Note: Staff should be encouraged to purchase their own supplies for use should they develop influenza symptoms

so as to minimise the risk of spreading the virus to others.

Further Information about use (donning, removal and disposal) of Personal Protective Equipment is

available at: www.cdc.gov/ncidod/dhqp/ppe.html

3.0

Respiratory Hygiene/Cough Etiquette for Individuals

Human influenza is transmitted from person to person primarily via virus-laden large droplets (particles >5

μm in diameter) that are generated when infected persons cough or sneeze; these large droplets can then be

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN

BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 27 of 31

directly deposited onto the mucosal surfaces of the upper respiratory tract of susceptible persons who are

near (i.e., within 3 feet) the droplet source.

Transmission also may occur through contact with infectious respiratory secretions both directly (from

person-to-person) and indirectly (by touching contaminated hard surfaces or objects).

The following simple hygiene precautions are important to minimise potential influenza

transmission.

To prevent the transmission of influenza (and other respiratory infections) all-year-round, the following

measures to contain respiratory droplets are recommended for all individuals with symptoms of a

respiratory infection:

 Cover your cough (i.e. cover the nose/mouth when coughing or sneezing)

 Use tissues to contain respiratory secretions and dispose of them in the nearest waste

receptacle after use

 Wash hands with soap and water, alcohol-based hand rub, or antiseptic handwash) after

having contact with respiratory secretions and contaminated objects/materials

In addition, during periods of increased respiratory infection (e.g., when there is increased absenteeism

in schools and work settings or reports of influenza outbreaks)

 Wear a mask if you are coughing or sneezing - either a procedure mask (i.e., with elastic ear

loops) or a surgical mask (i.e., with ties) may be used to contain respiratory secretions (an N-95

respirator or equivalent is not necessary for this purpose)

 Stay at least 1 meter (3 feet) away from other people and avoid traditional greetings (i.e shaking

hands etc) where possible

Workplaces should ensure the availability of materials such as:

 Tissues and no-touch receptacles for used tissue disposal

 Conveniently located dispensers of alcohol-based hand rub and, where sinks are available, ensure

that adequate supplies of soap and disposable towels are available

 Disposable masks and no-touch receptacles for used mask disposal

 Relevant Multi-lingual Posters, such as the following from US CDC, are available from many

local health authorities:

“Cover Your Cough” - for use in the workplace

www.cdc.gov/flu/protect/covercough.htm

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN

BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 29 of 31

4.0

Influenza Vaccination

Vaccination against Seasonal Influenza

Vaccination is the principal measure for preventing seasonal influenza and reducing the impact of

epidemics. Various types of influenza vaccines have been available and used for more than 60 years. They

are safe and effective.

Constant genetic changes in influenza viruses mean that the composition of the vaccine must be adjusted

annually to include the most recent circulating influenza viruses. The effectiveness of the vaccine depends

on the degree of similarity between the viruses in the vaccine and those in circulation. Seasonal influenza

vaccine will not protect against avian influenza or a new pandemic influenza strain. However, it is an

effective countermeasure against seasonal influenza, particularly for priority groups most at risk.

WHO and the Centres for Disease Control (US) advice is that all individuals who are at risk of

complications should be vaccinated against seasonal influenza. The priority groups at risk are listed below.

Local licensing requirements will determine the availability of seasonal influenza vaccines in each country.

Staff in the priority groups listed below should consider vaccination. Frequent business travellers and other

staff are also encouraged to take advantage of this protective measure.

The local country or expatriate medical plan will determine if cover is available for the cost of seasonal

influenza vaccination.

For frequent business travellers, BP will generally cover the cost of seasonal influenza vaccination in line

with the travel vaccination policy.

In other situations BP will act in line with national health recommendations and practice in supporting any

local vaccination programmes for influenza. The aim will be to ensure consistency of cover on a national

basis, rather than a segment or business unit basis

However, some higher risk situations, such as staff working on offshore installations and in other confined

accommodation, may require special consideration. BP Az SPU Health Team arranges Flu Vaccination

Campaign for all Az SPU employees each year.

Priority groups for whom annual Seasonal Influenza Vaccination is recommended:

 Children aged 6-59 months;

 Women who will be pregnant during the influenza season;

 Persons aged > 50 years;

 Adults and children who have:

- chronic disorders of pulmonary or cardiovascular systems, including asthma (hypertension is

not considered a high-risk condition);

- required regular medical follow-up or hospitalization during the preceding year because of

chronic metabolic disease

(including diabetes mellitus),

renal

dysfunction,

haemoglobinopathies, or immunodeficiency

(including immunodeficiency caused by

medications or by human immunodeficiency virus);

- any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other

neuromuscular disorders) that can compromise respiratory function or the handling of

respiratory secretions, or that can increase the risk for aspiration.

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN

BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 30 of 31

 Children and adolescents (aged 6 months-18years) who are receiving long-term aspirin therapy

and, therefore, might be at risk for experiencing Reye syndrome after influenza infection;

 Residents of nursing homes and other chronic-care facilities that house persons of any age who

have chronic medical conditions

 Persons who live with or care for persons at high risk for influenza-related complications,

including healthy household contacts and caregivers of children aged 0-59 months; and

 Health-care workers.

The following table outlines the features and potential availability of influenza vaccines:

Seasonal Flu Vaccines

Avian Flu H5N1 Vaccines

Pandemic Flu Vaccines

 Reformulated every year

 Human H5N1 vaccines have

 Not available for the first wave

according to expected flu

been developed in a number of

of a pandemic

strains

countries (incl. US, China,

 Take 6-9 months to be available

 Effectiveness dependent of

Australia)

in significant amounts

match with actual circulating

 May provide some cross-

 Production limited by world

strains

protection in Pandemic if it

capacity (and eggs)

 World capacity 300 million

emerges from Avian flu

 “Reverse-genetics” and tissue

doses per year

 Production limited by world

culture vaccines may speed-up

 Currently made from chicken

capacity (currently 300 million

production

eggs

doses per year)

 Tissue culture vaccines under

development

Vaccination against Pandemic Influenza

When a new pandemic virus strain emerges it would be a number of months before a vaccine would be

available. It should be noted that any new pandemic vaccine will initially be in short supply and priority

will need to be given to those most at risk.

The BP Health team will closely follow the development, protective effect and safety of any new

pandemic vaccine and will make recommendations as soon as a vaccine is available.

Pneumococcal vaccination

Pneumococcal pneumonia is a major cause of illness and death all over the world and is a possible

complication of influenza. The currently licensed pneumococcal vaccine has an overall protective efficacy

of about 60%-70%.

Personnel at particular risk of the bacterial pneumonia complication of influenza (including those

with chronic diseases such as congestive heart failure, emphysema, diabetes mellitus, chronic liver

disease, and those who are otherwise immune compromised) should consider immunization against

pneumococcal pneumonia.

5.0 Attachments

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN

BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Pandemic Preparedness Medical Response Plan

Page 31 of 31

Avian FLu .doc

Swine flu.doc

Revision/Review Log

Revision Date

Authority

Custodian

Revision Details

25 October 2009

Almaz Agazade -

Shahla Seyidova -

Initial Issue

Health Manager

Occupational Health

Advisor

24 September 2010

Health

Occupational Health

Section 1:

Manager/Almaz

Adviser/Shahla Seyidova

Agazade

Health Manager’s Contact

details was updated.

Section 2.5:

 Added information from

EMEA on Tamiflu shelf life

 Press release from EMEA

is attached

 Zabrat heliport was

changed to Baku sea port

in all attachments.

 SPS back up clinic was

removed from referral flow

charts in attached

documents and replaced

 Research institute of lung

diseases.

Section 2.8.1:

In list of Tamiflu storages SPS

back up clinic was replaced by

BP Baku In House OH clinic

Control Tier:

<<2>>

Revision Date: 25 September 2010

Document Number: << AZSPU-HSSE-DOC-00132-2>>

Print Date:

2/1/201110/26/2010

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED VERSION OF THIS DOCUMENT CAN

BE FOUND AT http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU List of HSE Definitions

Page 2 of 27

1.0 Purpose/Scope

The purpose of this document is to provide definitions for terms used in the Azerbaijan

Strategic Performance Unit (AzSPU) Health, Safety and Environment (HSE) procedures,

and other related documentation. Individual HSE documents may also list definitions for

terms unique to that document.

2.0 Definitions

Alphabetic List of definitions

The table below lists the terms included alphabetically, with links provided to each term.

Accident

Accountability

ACG

AIOC

ALT

Annual Plan

Assurance

ATS

Audit

Auditor

Audit Finding

Audit Owner

Audit Plan

Audit Protocol

AzSPU

Behavior-based Safety process

BP requirements

BPCS

BTC

Business Processes

CAP

CMER

Compliance Audits

Confidential / Secret

Contingency plan

Continuous Improvement

Contractor

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 3 of 27

Contractor Management Representative

Contractor Oversight

Controlled Document

Controlled Document Master List

Corrective Action

CoW

CTM

C&WP

DAFWC (Day Away From Work Case)

Defect

Document

Document Authority

Document Custodian

Document Control Specialist/Administrator

Drugs and Alcohol

Elements of Operating

Employees

Entity or BP Entity

Entity Business Strategy

Environment

Environmental Aspect

Environmental Assessment (EA)

Environmental Event

Environmental Impact

Environmental Management System Audit

Environmental Objective

Environmental Performance

Environmental Policy

Environmental Requirements

Environmental Target

EOP

ERP

ESAP

ESIA

ESMS

External Third-Party Audits

Externally verified statements & ISO certification

Facility

Fatality

Fatigued

Fire

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 4 of 27

First Aid

Fit for service

Fitness for task

Formal Independent Audit

Gap Assessment Tool

GHG

GHG Direct Emissions

GHG Indirect Emissions

Group Defined Practice

Group Essentials

Group Enduring Metrics

Group Recommended Practice

HACCP

Hazardous Waste

Health Surveillance

HGA

High Potential Incidents (HiPo)

HSE

HSE Liaison

HSSE Management System

HSSE Policy

HSSE&S MS Management Representative

Human Factors

IEMP

IGA

Implement

Incident Commander (IC)

Injury / Illness

Interested Party

Internal Audit

ISO 14001

Job Description

Journey Management Plan (JMP)

KPI

Leading and Lagging Indicators

Legal and Regulatory requirement

Legal and Regulatory HSSE requirements

Line Management

Local OMS Handbook

Major Accident Risk (MAR) Assessment

Major Incident

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 5 of 27

Major Operating Sites

Management Programme

Management Reviews

Management System

Management System Audit

Medical Confidentiality

Medical treatment

MENR

Major Incident

Major Operating Sites

Management System

Medical Confidentiality

MIA (Major Incident Announcement)

MoE

MSDS

Near Miss

NREP

Noncompliance

Nonconformity

OCD

Occupational Illness

Occupational Injury

Objective Evidence

Obsolete Document

OHAIRS

OMS

OHAIRS

Operator

Operating

Operating Management System Framework

Operational Control

Operational Program

Organization

Other Requirements

Oversee

Oversight

Performance improvement cycle

Possible Violation

Potential Violation

Prevention of Pollution

Preventive Action

Principles

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 6 of 27

Procedure

Process Safety

Process safety incident

Produced water

Program

PSA

Psychosocial Factors

QPR

Record

Risk

Risk Reduction Measure

Risk Register

Safe, Responsible and Reliable

Safety and Production Critical

SCP

SDA

SOCAR

SSOW

SOC

Social Aspect

Social Management System Audit

Social Objective

Social Performance

Social Policy

Social Target

SPU

STEP

Sub-elements

Supplier Performance Lead

Task Description

Task Statement

Technical Authority

Third Party

Training

TVAR

Unsafe/Unhealthy Condition

Vendor

Verified Site Report

Violation

VTA

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 7 of 27

Waste

Waste Management

Workforce

WREP

Accident - Any event results in injury, and/or damage and/or loss

Accountability - The ultimate responsibility for an area of authority defined by the

individual‟s Job Description, and will include authority delegated to a subordinate albeit

temporary or permanent

ACG - Azeri, Chirag and deep water Gunashli

AIOC - Azerbaijan International Operating Company

ALT - Azerbaijan Leadership Team - the highest management level of Azerbaijan

Strategic Performance Unit management.

Annual Plan - The entity annual plan is the documented outcome of the annual planning

process each part of the business uses to address risks, performance delivery and

performance improvement opportunities and allocate resources and budgets

accordingly.

Assurance - The justified confidence that the system of internal control is in place, is fit

for purpose, and is working as intended. Activities being undertaken to be certain that

the system of internal control is embedded and working as intended include self-

verification activities, challenge from outside the line, and rigorous and objective

assessment through audits.

ATS - Action Tracking System.

Audit - A systematic, independent evaluation to determine whether or not the health,

safety, security and environmental management system and its operation comply with

planned arrangements, and whether or not the system is implemented effectively, and is

suitable to fulfil the company‟s health, safety, security and environmental policy and

objectives.

Auditor - Person with the competence to conduct an audit.

Audit Finding - result of the evaluation of the collected audit evidences against audit

criteria.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 8 of 27

Audit Owner - The person in the audited organization who sanctions the audit and/or is

accountable for closing audit findings.

Audit Plan - A planning tool developed for the audit prior to the work taking place. It is

a high level summary of audit objectives, scope, criteria, schedule, logistics, safety

considerations, and team membership.

Audit Protocol - An audit-specific document that addresses the requirements to be

reviewed during the course of the audit, depending on the audit scope and objectives.

AzSPU - Azerbaijan Strategic Performance Unit - the BP Group Strategic Performance

Unit involved in the exploration, drilling, and/or production and transportation of oil and

gas in Azerbaijan, Georgia and Turkey and its territories.

BP - The BP Group

BPCS - BP Exploration (Caspian Sea) Ltd.

Behaviour-based Safety Process - A behaviour-based safety process involves the

workforce in continually improving HSE behaviours through systematic identification of

target safe behaviours, observation, coaching, recording and action. The Safety

Observation Conversations (SOC) process is an example of a behaviour-based safety

process.

BP Requirements - The total of all the BP Group requirements defined by the functions.

BTC - Baku Tbilisi-Ceyhan oil pipeline

Business Processes- Activities undertaken to achieve a specific business outcome.

CA - Central Azeri Platform

CAP - Compliance Assurance Process - a process designed to assure that legal and

other requirements are identified and communicated, and that responsibilities and

internal control mechanisms are in place to maintain compliance with the requirements.

The process also incorporates means for detecting non-compliance and taking corrective

action on the findings.

CMER- Crisis Management and Emergency Response

Compliance Audits - Audits performed to assess compliance with HSSE&S legal and

other requirements.

Confidential/Secret

- Confidential information is information the disclosure,

modification, misuse, or destruction of which could be significantly prejudicial to the

interests of BP businesses and functions, or could cause significant embarrassment or

difficulty for BP businesses and functions or their employees. Personal data must be

classified as Confidential.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 9 of 27

Contingency plan - A pre-established plan to mitigate an unusual situation which has

the potential for harm, which incorporates the best use of local as well as remote

facilities and resources.

Continuous Improvement - Doing better as a result of regular, consistent efforts rather

than episodic or step-wise changes, producing tangible positive improvements either in

performance, efficiency or both. (Centre of Chemical Process safety).

Contractor - An individual under a contractual relationship to supply BP plc or one of its

subsidiary companies with goods and/or services.

A contractual relationship covers:

-All individuals contracted directly or sub-contracted

-All employees of companies contracted directly or sub-contracted

-All situations where a contract has not been raised but BP‟s procurement policy would

normally expect there to be a contract in place. This applies to all levels including sub-

contracted relationships.

Contractor Management Representative - An employee of the contractor who is the

primary contact for the Supplier Performance Lead or HSE Liaison.

Contractor Oversight - Monitoring and reporting of a contractor‟s operations and

HSSE&S performance.

Controlled Document - Documents, records and information that are required to

maintain safe, responsible and reliable operating activity. These could include but are

not limited to procedures & practices, technical studies, drawings, P&IDs, models,

processes, hazard lists, and technical, design and operations data, and product,

medical, occupational exposure and compliance-related records..

Controlled Document Master List - A list of all documents that are controlled.

Corrective Action - Action to eliminate the cause of a detected nonconformity or

noncompliance.

CoW - Control of Work

CTM - Compliance Task Manager is an electronic compliance matrix that helps

businesses manage the relationships between applicable legal requirements,

compliance tasks, accountable BP employee positions, operational controls and

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 10 of 27

completion evidence document. The tool is provided to help businesses maintain

justifiable confidence in consistently meeting their HSSE legal obligations.

C&WP - Compression and Water Injection Platform

DAFWC (Day Away From Work Case) - A work-related injury or illness which has

either of the following consequences:

The member of the BP Workforce could not have worked on any day after the injury or

illness, irrespective of whether there was scheduled work.

The member of the BP Workforce comes to work even when a physician or other

licensed health care professional recommends that the individual stays at home.

Defect - Any act or condition which could be changed so as to stabilize or improve

performance.

Document - Information and its supporting medium. The medium can be paper,

magnetic, electronic or optical computer disc, photograph or master sample, or a

combination thereof.

Document Authority - The individual that has executive authority for the document,

making it binding on the organizational entity (e.g., Upstream, Strategic Performance

Unit (SPU), Performance Unit (PU), operations asset [OA], operations site (OS), etc).

Document Custodian - The individual who, in most cases, is the document author or

subject matter expert responsible for the accuracy and management of the document.

Document Control Specialist/Administrator - The person assigned to assist a SPU

and/or PU in receiving and managing original document copies, assigning control

numbers, updating and maintaining master lists, making notification of required reviews,

and removing obsolete documents from and posting new and/or updated documents for

the HSSE&S MS.

Drugs and Alcohol

- includes alcohol, controlled substances, drugs and other

medication (whether illegal, legitimately prescribed or over-the-counter) which can be

inhaled, injected or ingested, and which are capable of affecting performance or

judgment.

EA - East Azeri Platform

Elements of Operating - Describe operating in BP, include the eight elements of

Leadership, Organization, Risk, Procedures, Assets, Optimization, Privilege to Operate,

and Results. Each element and sub-element includes an operating principle.

Employees - People directly employed by a company. These can be BP employees if

working directly for BP or contractor employees if working directly for a contractor.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 11 of 27

Entity or BP Entity - An organizational unit within BP which may be a Performance

Unit, Business Unit, Strategic Performance Unit, Segments or some logical sub group of

one of these, defined by the Segment, Function or Region. Each operating entity will

have a consistent local Operating Management System documented in an OMS

Handbook.

Entity Business Strategy - A multi year (typically 5) look ahead identifying key business

risks and opportunities, outlining the actions needed to address them and estimating

resource needs.

Environment - Surroundings in which an organization operates, including air, water,

land, natural resources, flora, fauna, humans, and their interrelation.

Environmental Aspect -Element of an organization‟s activities or products, or services

that can interact with the environment.

Environmental Assessment (EA) - Local, scheduled, documented self-verifications

that monitor key performance indicators to determine if process outcomes meet

corporate and environmental requirements. Environmental Assessments are conducted

internal to, or in support of, the operation being evaluated. Environmental Assessments

are distinguished from Formal Independent Audits performed by personnel independent

of the operations.

Environmental Event - A situation where a person observes or becomes aware of a

fact or facts that suggest an environmental issue, including, but not limited to

environmental nonconformance and potential or actual violations.

Environmental Impact - Any change to the environment, whether adverse or beneficial,

wholly or partially resulting from an organization‟s environmental aspects.

Environmental Management System Audit - Systematic and documented verification

process of objectively obtaining and evaluating evidence to determine whether an

organization‟s EMS conforms to the EMS audit criteria set by the organization, and for

communicating the results of this process to management and other affected parties.

Environmental Objective

- Overall environmental goal, consistent with the

environmental policy, that an organization sets itself to achieve.

Environmental Performance - Measurable results of an organization‟s management of

its environmental aspects. In the context of EMS, results can be measured against the

organization‟s environmental policy, environmental objectives, environmental targets and

other environmental performance requirements.

Environmental Policy - Overall intentions and direction of an organization related to its

environmental performance as formally expressed by top management. The

environmental policy provides a framework for action and for the setting of environmental

objectives and environmental targets.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 12 of 27

Environmental Requirements

- Applicable international, national, and local

environmental statutes, regulations, enforceable agreements, project-specific

agreements, lender requirements, agency orders, and permits

(also termed legal

requirements).

Environmental Target

- Detailed performance requirement, applicable to the

organization or parts thereof, that arises from the environmental objectives and that

needs to be set and met in order to achieve those objectives.

EOP - Early Oil Project

ERP - Emergency Response Plan

ESAP - Environmental and Social Action Plan.

ESIA - Environmental and Social Impact Assessment.

ESMS - Environmental and Social Management System. That part of an organization‟s

management system used to develop and implement its environmental / social policies

and manage its environmental / social aspects. A MS is a set of interrelated elements

used to establish policy and objectives and to achieve those objectives. A MS includes

organizational structure, planning activities, responsibilities, practices, procedures,

processes and resources.

External Third-Party Audits - Audits conducted by independent third parties outside of

BP. These types of audits include EMS certification to ISO 14001 and other required

external audits.

Externally verified statements & ISO certification - BP AzSPU major sites that have

their Environmental Management Systems

(EMS) certified against the ISO

14001

Standard and an externally Verified Site Report which is publicly available.

Facility - is a generic term used to denote any organizational unit below the BP entity

level. Could denote a site, uniy, etc.

Fatality -

 BP AzSPU

Any incident that results in the death of a BP AzSPU Employee

and occurs in the BP Work Environment. This includes both work-related and non

work-related fatalities.

 Contractor

Any incident that results in the death of a BP Contractor and

occurs in the BP Work Environment. This includes both work-related and non

work-related fatalities.

 Third Party

Any incident that results in the death of a third party who is in or

impacted by the BP Work Environment. This includes both work-related and non

work-related fatalities.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 13 of 27

Fatigued - State of tiredness that is associated with long hours of work, prolonged

periods without sleep, or the requirement to work when the individual would normally be

resting. It is a result of physiological factors and is not a „state of mind‟.

Fire

- Any unintentional fire of any magnitude should be reported, including any

materials which have ignited resulting in flame or smoke, and including

unintentional electrical arcs.

This includes fires that are typically process-safety related. For example:

 A gas, oil or chemical release that results in a flame

 A tangible indication of a fire (e.g. soot on the inside of a distillation tower) where

no flame was actually seen

 A fire on a scaffold board in a process unit

 A fire in a vehicle parked by an operating unit

 A 120 or 220 volt shorted switch

 A fault in a motor control centre or electrical switch gear.

This also includes fires that are not typically process-safety related. For example:

 A paper or cardboard fire in a garbage / trash can in an office building

 A fire during equipment repair in a maintenance shop

 A solvent fire in a laboratory

 Smouldering rags in a pump house (no flame)

 A fire in a vehicle in a parking lot outside the facility fence.

First Aid - An incident is classified as a First Aid if the treatment of the resultant injury or

illness is limited to one or more of the 14 specific treatments below.

These are:

1. Using a non-prescription medication at non-prescription strength

2. Administering tetanus immunizations

3. Cleaning, flushing or soaking wounds on the surface of the skin

4. Using wound coverings such as bandages, gauze pads, etc; or using butterfly

bandages

5. Using hot or cold therapy

6. Using any non-rigid means of support, such as elastic bandages, wraps, non-

rigid back belts, etc

7. Using temporary immobilization devices while transporting as accident victim

8. Drilling of a fingernail or toenail to relieve pressure, or draining fluid from a blister

9. Using eye patches

10. Removing foreign bodies from the eye using only irrigation or a cotton swab

11. Removing splinters or foreign material from areas other than the eye by

irrigation, tweezers, cotton swabs or other simple means;

12. Using finger guards

13. Using massages, or

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 15 of 27

Fit for Service -The current condition of a piece of equipment is capable of operating at

defined operating conditions for a defined operating period.

Fitness for Task - Fitness to perform specific tasks that have been identified as carrying

risks that could harm the health and safety of themselves, others or the integrity and

safety of the operations. (i.e. assessment of eyesight for driving).

Formal Independent Audit - An independent review of business activities. It is a

systematic, documented process of collecting and evaluating factual evidence to confirm

an organization‟s adherence to corporate and environmental/social requirements. These

Formal Independent Audits are performed to objectively check BP AzSPU Upstream‟s

operations. Independent groups include BP AzSPU Upstream‟s internal audit group, BP

audit groups, contractors, and technical authorities from operations other than those

being audited. Lead auditors are independent of line responsibilities or Business Unit

affiliation.

Gap Assessment Tool (GAT) -The OMS Group Essentials Gap Assessment Tool

(GAT) - a group developed gap assessment tool for entities to identify and prioritise gaps

against the Group Essentials statements. The GAT is a web based tool, and is

accessible via the OMS Implementation website.

GHG - Greenhouse gases that alter the termal properties of the atmosphere. The main

greenhouse gases are condered to be water vapour, carcon dioxide, chloroflouro

carbons, halons and ozone.

GHG Direct Emissions - Emissions of greenhouse gases from sources that are under

the operational control of the company.

GHG Indirect Emissions - Emissions of greenhouse gases that are consequences of

the activities of the company but occur at sources outside the operational control

boundary.

Group Defined Practice (GDP) - The few (currently 13) group mandatory practices

defining engineering and operating Group requirements primarily focused on identifying,

prioritising and managing risk.

Group Recommended Practice (GRP) - Group engineering and operating practices

containing recommended practice that entities are encouraged to use to deliver the

Group Essentials. Refer to the Integrity Management GDP (GDP 5.0-0001) which

contains Group requirements for the application of Engineering Technical Practices

(ETPs) at entities.

Group Enduring Metrics - The measures used to monitor the delivery of the Group‟s

long-term objectives.

Group Essentials -These are a consolidated list of S&O Function controlled BP Group

requirements categorized against the sub-elements.

HACCP - Hazard Analysis Critical Control Points

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 16 of 27

Hazardous Waste - The sum of the operated direct hazardous waste disposed in tonnes

for the year being measured expressed as a percentage of the equivalent waste

disposed for 1999.

Hazardous Waste % =

Operated hazardous waste disposed

Operated hazardous waste disposed in 1999

Health Surveillance - The systematic monitoring of employees exposed to certain

health risks for early signs of biological changes that could indicate damaging exposure

to work related health risks. It seeks to confirm that where employees are potentially

exposed to known workplace hazards, the control measures are effective and the worker

is showing no harmful effect.

Health surveillance is appropriate where potential exposure to a workplace hazard has a

known health effect and there is a validated, reproducible and measurable biological

impact.

HGA - Host Government Agreement

High Potential Incidents (HiPo) - An Incident or Unsafe/Unhealthy Condition or near

miss where the most serious probable outcome is a Major Incident. In addition, this

includes any Loss of Primary Containment Incident where the potential severity is

classified at Level E or greater as defined in the Group-defined Operating practice

„Reporting HSSE and Operational Incidents‟.

HSE - Health, safety and environment

HSE Liaison - Individuals selected to assist in managing a contract.

HSSE Management System - The Company structure, responsibilities, practices,

procedures, processes and resources for implementing health, safety, security and

environmental management.

HSSE Policy - Overall intentions and direction of an organization related to its health,

safety, security and environmental performance as formally expressed by top

management.

HSSE&S MS Management Representative - An individual appointed by Senior

Management who, irrespective of other responsibilities, shall have defined roles,

responsibilities, and authority for:

 Ensuring that HSSE&S MS requirements are established, implemented, and

maintained to meet policy requirements, achieve objectives and targets, and

comply with legal and other requirements to which the organization subscribes

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 17 of 27

 Reporting on the performance of the HSSE&S MS to Senior Management for

review and as a basis for improvement.

Human Factors - Human factors consider how human and individual characteristics

combine with environmental, organisational and job factors to influence workplace

behaviour that could impact health and safety. They recognise that human error often

results from a misalignment between physical and behavioural characteristics of human

beings and the design of jobs, processes, equipment and conditions in the workplace.

Fatigue is a human factor that requires special attention to understand and prevent

accidents in the workplace.

IEMP - Integrated Environmental Monitoring Program

IGA - Inter Governmental Agreement

IM- Integrity Management (BP Group Standard)

Incident - An unplanned event or occurrence that affects or has the potential to affect

the health or safety, or security of:

people, or

assets, or

the environment.

Implement - Put in place a plan, process or procedure and act in accordance with it.

Incident Commander (IC) - An individual designated and trained to command and

control the company‟s emergency response efforts.

Injury/Illness - Injuries are a consequence of instantaneous events. Instantaneous

events are characterised by a sudden and unexpected physical change which occurs

over a short time and which results in immediate harm to people. A short time may be

described as the snap of your finger or a single breath. Therefore, conditions such as

sunburn, welders flash, friction blisters, or repetitive motion induced conditions are

illnesses. Back problems are always considered injuries.

Interested Party - Person or group concerned with or affected by the health, safety,

security, environmental or social performance of an organization.

Internal Audit - A systematic, independent and documented process for obtaining audit

evidence and evaluating it objectively to determine the extent to which the HSSE&S

management system audit criteria set by the organization are fulfilled.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 18 of 27

ISO 14001- ISO 14001 is the specific standard for Environmental Management Systems,

against which certification may be obtained. ISO is a leading international organisation

for standardisation

Job Description - A short document which sets out an employee‟s authority and

responsibilities in the job, who he/she reports to, and who reports to him; what his duties

are and the qualifications necessary to perform those duties.

Journey Management Plan (JMP) - The planned movement of people and equipment

from one place to another including communications, route, scheduled stops, hazard

warnings, provisioning, breakdown and other contingency.

KPI - Key Performance Indicator - a quantifiable measure used to monitor progress in

achieving objectives and targets.

Leading and Lagging Indicators

- Metrics used to measure and/or monitor

performance. Leading indicators measure the inputs leading to an outcome, and lagging

indicators measure the actual outcome.

Legal and Regulatory Requirements - Applicable obligations established by applicable

legislation, regulation, administrative order or notice, permit, consent decree or any other

similar instrument, and any legally binding commitment entered into by BP, where failure

to comply by BP is unlawful and enforceable by a court of law in the relevant jurisdiction.

Legal and Regulatory HSSE Requirements- Legal and regulatory requirements

relating to health, safety, security or the environment.

Line Management - Managers in the line organization that are directly accountable for

HSSE&S issues.

Local OMS Handbook - A document describing the local OMS for an operating entity.

Describes how the OMS framework is implemented in the operating entity, including how

the local OMS is integrated with local business processes. Describes how the operating

entity captures learnings and continuously improves performance.

Major Accident Risk (MAR) Assessment - A risk assessment undertaken using the

Group Major Accident Risk (MAR) process (ETP No. GP 48-50).

Major Incident- A health, safety, security or environmental Incident in which the actual

severity represents a Level A-D or E impact as defined in the Group-Defined Operating

Practice „Reporting HSSE and Operational Incidents‟.

Major Operating Sites - A site or grouping of sites that produce or manage petroleum,

chemical, or manufactured products where such products, their production processes, or

their exploration processes have the potential to cause significant impact on the

environment or the safety and health of employees, neighbours, or consumers. Group

S&O Function will maintain and publish a list of major operating sites.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 19 of 27

Management Programme - Describes the activities required to achieve specific

objectives and targets e.g. the Waste Management Programme details actions,

responsibilities and accountabilities for achieving waste related objectives and targets.

Management Reviews - Formal, documented review carried out by an entity leadership

team to review the effectiveness of the entity local OMS, and to identify, implement and

sustain improvements.

Management System - A management system is the framework of processes and

procedures used to ensure that an organization can fulfill all tasks required to achieve its

objectives

Management system audit - audit of conformance with the management programme

requirements in OMS

Medical Confidential - The ethical principle or legal right that information relating to a

patient will not shared and will be kept safe by health professionals, unless the patient

gives consent permitting disclosure. All clinical data have a degree of confidentiality and

shall be treated as controlled documentation.

Medical Treatment (MT) - An incident is classified as a Medical Treatment (MT) case

when the management and care of the patient to address the injury or illness is above

and beyond First Aid. Medical Treatment does not include the conduct of diagnostic

procedures, such as x-rays and blood tests, including the administration of prescription

medications used solely for diagnostic purposes.

MENR - Ministry of Ecology and Natural Recourses (Azerbaijan)

MIA (Major Incident Announcement) - A Major Incident is an incident, including a

security incident, involving any one of the following:

 A fatality associated with BP operations

 Multiple serious injuries

 Significant adverse reaction from authorities, media, NGOs or the general public

 Cost of accidental damage exceeding US $500,000

 Oil spill of more than 100 barrels, or less if at a sensitive location (1 barrel = 159

liters)

 Release of more than ten tonnes of a classified chemical.

MoE - Ministry of Environment (Georgia)

MSDS - Material Safety Data Sheet issued by manufacturer of chemical substances that

sets out the hazards likely to be encountered by those who come into contact with the

substance. The sheet may also identify recovery procedures following adverse exposure

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 20 of 27

Near Miss - An event that under slightly different circumstances could have resulted in

an HSSE&S requirement violation, or a nonconformance.

NREP - Northern Route Export Pipeline

Noncompliance - Noncompliance is a failure to meet regulatory or other requirements.

Nonconformity - Any deviation from established procedures, programs, and other

arrangements related to the HSE MS.

OCD - Organizational capability development

Occupational Illness - An occupational illness is any abnormal condition or disorder,

other than one resulting from an occupational injury, caused by exposure associated with

the BP work environment. This includes acute and chronic illnesses or diseases which

may be caused by inhalation, absorption, ingestion, or direct contact with physical,

chemical, biological or psychological hazards in or associated with the working

environment.

Occupational Injury - An occupational injury is any harm to an individual caused by an

instantaneous event in the work environment. Instantaneous events are characterised by

a sudden and unexpected physical change which occurs over a short time and which

results in immediate harm to people. A short time may be described as the snap of your

finger or a single breath.

Objective Evidence

- A verifiable fact gained through the examination of

documents/records, the observation of field activities or conditions, or conversations with

persons who have firsthand knowledge of the facts.

Obsolete Document - A document that is no longer applicable to the HSSE&S MS

and/or has been replaced by a revised document.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 21 of 27

OMS - Operating Management System, provides a systematic and consistent approach

for managing our operating activities, and delivering competitive performance while

meeting BP‟s commitment to HSSE performance

OHAIRS - Occupational Health and Illness Reporting System

Operator - A specific company or business entity formally designated as managing day-

to-day operations of a given asset.

Operating - All forms of business activity that are involved in managing Projects and

Operations including but not limited to all aspects of Engineering, Marine and HSSE

activities.

Operating Management System (OMS) Framework - A control process that describes

the BP Elements of Operating, Performance Improvement Cycle, and the requirement for

development of a local OMS at each BP operating entity. The framework operates by

applying the OMS Continuous. Improvement process to local business processes to

deliver the outcomes summarized in the eight Elements of Operating. The term is

synonymous with „BP Operating Management System‟.

Operational Control - An implementing procedure, physical control, checklist, training,

employee expertise, or other means of controlling operations to manage significant

environmental aspects and/or legal and other requirements. Examples of physical

controls can include valves, automatic shutoff devices, engineered solutions, signage, etc.

Operational controls, in the form of procedures, stipulate operating criteria.

Operational program - the procedures and processes that specify how operations

barriers are to be implemented, e.g control of work programme, waste management

programme.

Organization - Company, corporation, firm, enterprise, authority, or institution, or part or

combination thereof, whether incorporated or not, public or private, that has its own

functions and administration.

Other Requirements - Requirements to which a SPU subscribes that are in addition to

legal requirements. A BP example is Getting HSE Right.

Oversee - To monitor.

Oversight - Monitoring and Reporting of performance.

Performance Improvement Cycle (PIC) - The annual systematic improvement process

applied at each entity based on the Plan/Do/Check/Act cycle, but with Intent and Risk

Assessment and Prioritisation steps added at the start of the process. The specific

requirements of the PIC are detailed in OMS Part 3.

Possible Violation - A HSSE&S event that may constitute a violation after a complete

review of the facts, or upon further legal analysis of applicable requirements.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 22 of 27

Potential Violation - A possible violation.

Prevention of Pollution - Use of processes, practices, techniques, materials, products,

services or energy to avoid, reduce or control (separately or in combination) the creation,

emission or discharge of any type of pollutant or waste, in order to reduce adverse

environmental impacts. Prevention of pollution can include source reduction or

elimination, process, product or service changes, efficient use of resources, material and

energy substitution, reuse, recovery, recycling, reclamation and treatment.

Preventive Action - An action to eliminate the cause of a potential nonconformity.

Principles - High level statements summarizing the intent of each Element and sub

element of Operating. These Principles are used by members of the operating

community to guide judgments and support decision making, especially in the absence

of any specific group or segment requirement.

Procedure - A specified way to carry out an activity or a process.

Process Safety - to manage the integrity of hazardous operating systems and

processes by applying good design principles, engineering and operating practices

which prevent and control incidents that have the potential to release hazardous

materials or energy.

Process safety incident - An incident related to process safety, a disciplined framework

for managing the integrity of hazardous operating systems and processes by applying

good design principles and engineering practices, dealing with the prevention and

control of incidents that have the potential to release hazardous materials. Such

incidents can cause toxic effects, fire, or explosion and could ultimately result in serious

injuries, property damage, lost production and environmental impact.

Produced water - Formation water from the oil reservoir that is co-produced with the oil

and subsequently separated. Separated perched and condensed water from

gas/condensate fields is included in this category.

Program

- the procedures and processes that specify controls or barriers.

“Programmes” can be operations programmes or management programmes.

PSA - Production Sharing Agreement.

Psychosocial Factors - Factors that may affect employees‟ psychological response to

their work and workplace conditions (including working relations). They may appear

when there is a mismatch between the job requirements and the capabilities, resources

and needs of the individual. Examples include: high workloads, tight deadlines, lack of

control of the work and working methods. Psychosocial factors are important as they

may contribute to stress and musculoskeletal disorders.

QPR - Quarterly Performance Review

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 23 of 27

Record - A document stating results achieved or providing evidence of activities

performed.

Risk - A measure of loss / harm to people, the environment, compliance status, Group

reputation, assets or business performance in terms of the product of the probability of

an event occurring and the magnitude of its impact.

Risk Reduction Measures - Measures and actions taken to reduce risk or prevent an

incident occurring, and/or control its impact or frequency, and/or mitigate its effect on

people, the environment, or our business. These measures and actions should be

considered in the following order of preference: Elimination, Prevention, Control,

Mitigation, and Emergency Response. Further detail and information can be found in

GDP 31-00-01 Assessment, prioritisation and management of risk.

Risk Register - A document that identifies hazards and risks relating to the operating

activity of the entity. It will detail the impact and probability of risks and identify plant,

process, people and performance risk reduction measures to manage the risks. (Further

detail in GDP 31-00-01 Risk assessment, prioritisation and management).

Safe, Responsible and Reliable - An outcome where all aspects of Health, Safety,

Security and Environment are well managed and in line with legal and regulatory HSSE

requirements and plant and equipment are operated to achieve planned performance.

Safety and Production Critical - Very important to achieving safe, responsible and

reliable operating.

SCP - South Caucasus Pipeline

SD - Shah Deniz

SDA - Shah Deniz Alpha platform

SOCAR - State Oil Company of the Azerbaijan Republic

SSOW - Safe System of Work

SOC - Safety Observation Conversation

Social Aspect - Elements of an organization‟s activities, products, and services that can

interact with the community or wider stakeholders.

Social Management System Audit - Systematic and documented verification process

of objectively obtaining and evaluating evidence to determine whether an organization‟s

SMS conforms to the SMS audit criteria set by the organization, and for communicating

the results of this process to management and other affected parties.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 24 of 27

Social Objective

- Overall social goal, arising from the social policy, that an

organization sets itself to achieve, and that is quantified where practicable.

Social Performance - Measurable results of the SMS, related to an organization‟s

control of its social aspects, based on its Social Policy, objectives and targets and its

compliance with applicable social requirements.

Social Policy - Statement by an organization of its intentions and principles in relation

to its overall social performance, that provides a framework for action and for the setting

of its social objectives and targets.

Social Target

- Detailed performance requirement, quantified where practicable,

applicable to the organization or parts thereof, that arises from the social objectives and

that needs to be set and met in order to achieve those objectives.

SPU - Strategic Performance Unit - a formally recognized discrete business organization

within the BP Group.

Spill (or hydrocarbon spill) - All spills of hydrocarbon greater than or equal to 1 barrel

(bbl). Spills less than 1 barrel are not included in this metric but must be held locally,

typically in Traction.

(1 barrel = 159 litres = 42 US gallons)

STEP - Sangachal terminal Expansion Project

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 25 of 27

Sub-Elements - The sub-elements (currently 48) of the Elements of Operating provide a

more detailed list of operating activities, which are dependent on each other and need to

be selectively and systematically managed using OMS.

Supplier Performance Lead - Individuals selected to assist in overseeing a contract

Task Description - Description of Compliance Task requirement, including actions

required to complete the Task

Task Statement - Statement to summaries the Compliance Task requirement

Technical Authority

(health

/ safety

/ security

/ environmental

/ social

management system / external affairs specialist, or other designated HSSE

personnel) - provide input in terms of technical interpretation of Legal and Other

Requirements and changes to Legal and Other Requirements, as required.

Third Party - Person associated with the work, but not a member of our work force.

Training - The process of imparting specific skills and understanding to undertake

defined tasks.

TVAR - Total Vehicle Accident Rate

Unsafe/Unhealthy Condition- Any departure from the required or expected

performance or condition of equipment (Plant), procedures (Process), or People, which if

not addressed could result in an Incident, or make a consequence of an incident more

severe. For example, thinning of pipes due to corrosion or excessive work hours

causing fatigue.

Vendor - A Supplier that provides tangible material or equipment. Company defines any

Vendor that provides On-Site services other than delivery as a Contractor.

Verified Site Report

- An externally verified document which represents the

performance of a particular facility or cluster of facilities that has been published on BP

AzSPU Official web-site.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 26 of 27

Violation - A failure to comply with an HSE requirement.

VTA - Virtual Training Assistance

WA - West Azeri Platform

Waste - Any material, (solid, liquid or gas), which is introduced into work location as a

product of the work but which fulfils no further useful purpose, at that location.

Waste Management - A system to achieve reduction, re-use, reclamation, recycling and

responsible disposal of materials

Workforce - comprises all BP employees, BP Contractors and all BP Directors

WREP - Western Route Export Pipeline

3.0 General Requirements

 RD 0.0-0001 BP Group OMS Glossary Reference Document

 BP Group HSE Reporting Definitions

 ISO 14001 - 3.0 Definitions

 OHSAS 18001 - 3.0 Terms and Definitions

4.0 Responsibilities

Not applicable.

5.0 Procedure

Not applicable.

6.0 Key Documents/Tools/References

Not applicable.

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU List of HSE Definitions

Page 27 of 27

Revision Log

Revision Date

Authority

Custodian

Revision Details

December

26,

Gunther

Yuliy Zaytsev

Initial issue.

2005

Newcombe

November

13,

Gunther

Yuliy Zaytsev

Additional definitions added, number of

2006

Newcombe

existing definitions revised.

November

29,

Yuliy Zaytsev

Farid Jafarov

Additional definitions have been added

2007

from the list of BP Group HSSE

reporting definitions,

number of

existing

definitions

revised and

amended.

January 06, 2009

Yuliy Zaytsev

Idrak Nazarov

Additional definitions were added

January 18, 2010

Yuliy Zaytsev

Idrak Nazarov

Document was revised in accordance

with new OMS Glossary & Definitions,

Additional Definitions were added

where the other‟s definitions were

revised due to new OMS language

Control Tier:

2-AzSPU

Revision Date: January 18, 2010

Document Number: AzSPU-HSSE-DOC-00021-2

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE CONTROLLED

VERSION OF THIS DOCUMENT CAN BE FOUND AT http://docs.bpweb.bp.com/dkazspu/

AzSPU Environmental Risk Assessment Procedure

Page 1 of 19

AzSPU

Environmental Risk Assessment

Procedure

Procedure for Environmental Risk Assessment of

Chemicals and Hazardous Substances

AZSPU-HSSE-DOC-00120-2

Authority:

AzSPU Environmental

Custodian:

AzSPU Senior Environmental Advisor

Manager / Faig Askerov

(monitoring)/ Afag Abbasova

Scope:

AzSPU (Azerbaijan)

Document

Administrator:

<< Document Asset Technician Name >>

Issue Date:

31 October 2007

Issuing Dept:

HSE & Technical Directorate

Revision Date:

28 January 2010

Control Tier:

2-AzSPU

Next Review

31 January 2011

Date:

Control Tier:

<<Tier-2-AzSPU>>

Revision Date: 31 January 2010

Document Number: << AZSPU-HSSE-DOC-00120-2>>

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE

CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Environmental Risk Assessment Procedure

Page 2 of 19

1.0 Purpose/Scope

This procedure describes the process of environmental risk assessment (ERA) for potential

release of chemicals and hazardous substances.

This is a Tier 2 procedure applicable to AzSPU upstream operations for marine waters, and

as such applies primarily to planned or potential

(accidental) release of chemicals and

hazardous substances into the Caspian Sea.

The purpose of the procedure is to define:

circumstances under which an ERA is necessary;

actions and information required to complete ERA.

While primarily applicable to AzSPU upstream operations for marine waters, the processes

outlined in this document may also be applied to any situation in which it is planned, or

considered possible, that there will be discharge to the environment of a chemical, hazardous

material, or effluent containing such substances or their wastes or reaction products.

This procedure does not replace, nor should it conflict with:

AzSPU Chemical and Hazardous Materials Management Procedure (AZSPU-HSSE-

DOC-00078-2);

Azerbaijan SPU Internal & External Material Release Reporting & Notification

Procedure (AZSPU-HSSE-DOC-00075-2)

The Azerbaijan SPU Spill to Sea Response Plan for Offshore Facilities (AZSPU-

HSSE-DOC-00018-3) or other spill response plans;

Incident Investigation and Reporting Procedure (AZSPU-HSSE-DOC-00054-2)

This procedure has been prepared with reference to:

AzSPU Chemical and Hazardous Materials Management Procedure (AZSPU-HSSE-

DOC-00078-2);

Azerbaijan SPU Internal & External Material Release Reporting & Notification

Procedure (AZSPU-HSSE-DOC-00075-2)

Definitions (AzSPU-HSSE-DOC-00021-2).

Caspian-specific Ecotoxicity Procedures: Methods Development and Implementation

(ERT 97/227) as approved by the Azerbaijan State Committee of Ecology September

2000.

Revision of this procedure and the operational controls detailed therein will be in accordance

with Document Management

(Document AzSPU-HSSE-DOC-00025-2) procedure as

appropriate.

Control Tier:

<<Tier-2-AzSPU>>

Revision Date: 31 January 2010

Document Number: << AZSPU-HSSE-DOC-00120-2>>

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE

CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Environmental Risk Assessment Procedure

Page 3 of 19

1.1 Limitations

As stated above, this procedure has been developed primarily to be applicable to the planned

or potential discharge from BP upstream operations into marine waters, and as such addresses

primarily issues surrounding chemical selection and use in operations on or around the

Caspian Sea.

The quantitative risk assessment procedure outlined in Section 5.3 assumes use of toxicity

data for Caspian Sea species. This data is based on acute toxicity response, and it should be

noted that issues relating to chronic toxicity response and potential bioaccumulation are not

addressed.

1.2 List of Abbreviations

AzSPU

Azerbaijan Strategic Performance Unit

COSHH

Control of Substances Hazardous to Health

CTM

Compliance Task Manager

ERA

Environmental Risk Assessment

ESIA

Environmental and Social Impact Assessment

PLONOR

Pose Little or No Risk to the Environment

PNEC

Predicted No Effect Concentration

OCNS

Offshore Chemical Notification Scheme

OECD

Organisation for Economic Co-operation and Development

HGA

Host Government Agreement

HSSE

Health, Safety, Security & Environment

HSSEMS

Health, Safety, Security & Environment Management System

MENR

Ministry of Ecology & Natural Resources

PLONOR

Pose Little or No Risk (to the Environment)

PSA

Production Sharing Agreement

Control Tier:

<<Tier-2-AzSPU>>

Revision Date: 31 January 2010

Document Number: << AZSPU-HSSE-DOC-00120-2>>

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE

CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Environmental Risk Assessment Procedure

Page 4 of 19

2.0 Definitions

For definitions common to the hazardous materials management refer to the AzSPU Chemical

and Hazardous Materials Management Procedure (AZSPU-HSSE-DOC-00078-2).

Refer to Document AzSPU-HSSE-DOC-00021-2 Definitions for definitions common to this

management system. Definitions specific to this procedure are included below:

Term

Definition

Bioaccumulation

The capacity of a chemical to be concentrated in biological tissue to levels

significantly higher than in the environment.

Chronic

A relatively long period of exposure, usually a significant proportion of the

life-span of the organism (often > 10%).

EC50

The median effective concentration. The concentration of a test material

required to cause a 50% effect on a test response such as immobilisation.

Effluent

A liquid discharge to surface waters from an industrial, urban or agricultural

process.

LC50

The median lethal concentration

- the concentration of test substance

estimated to cause mortality in 50% of the test population.

OECD

Organisation for Economic Co-operation and Development.

intergovernmental organisation. In the context of this work, OECD publishes

internationally-agreed standard methods for conducting toxicity tests on

chemicals. OECD also publishes the international guidelines on which

member states base their procedures and legislation for Good Laboratory

Practice.

OSPARCOM

An intergovernmental organisation formed by the merging in 1992 of the

(OSPAR)

OSLO Commission and the PARIS Commission. OSPAR co-ordinates

policy and legislation on the discharge of materials from land-based and sea-

based sources. Member nations implement OSPAR decisions through their

own national environmental legislation. Also issues PLONOR list.

PNEC

The Predicted No-Effect Concentration is the concentration of a chemical

below which exposure to a chemical is anticipated to have no impact on a

target species.

Control Tier:

<<Tier-2-AzSPU>>

Revision Date: 31 January 2010

Document Number: << AZSPU-HSSE-DOC-00120-2>>

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE

CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Environmental Risk Assessment Procedure

Page 5 of 19

3.0 General Requirements

3.1 Applicable standards

The following recognized international standards and legislation specific to the assessment of

environmental risk shall apply as a minimum:

OSPAR PLONOR list (acceptable candidate chemicals);

OSPAR list I and II and chemicals subject to OSPAR decisions on phasing out or

prohibition (unacceptable candidate chemicals);

Chemicals which have passed the OSPAR pre-screening process (e.g. chemicals on the

UK OCNS ranked list) (acceptable candidate chemicals).

3.2 Scheduling Requirements

While this procedure outlines the process for determining the requirement for an

environmental risk, and the general process for undertaking the risk assessment, it should be

recognised that in many (if not most) cases where an ERA is required both internal (AzSPU)

review and external (regulator) review and approval will be required before a chemical is

approved for use or a discharge allowed.

In instances where it is anticipated that an ERA may be required, sufficient time should be

allowed not just to undertake the ERA but to ensure that both the internal and external review

and approval process can be completed prior to the planned use of the chemical or discharge.

Control Tier:

<<Tier-2-AzSPU>>

Revision Date: 31 January 2010

Document Number: << AZSPU-HSSE-DOC-00120-2>>

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE

CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

AzSPU Environmental Risk Assessment Procedure

Page 6 of 19

4.0 Key Responsibilities

4.1 PU / Asset Environmental Team Leader

The applicable PU/Asset Environmental Team Leader/Environment Manager, or their

designee, shall be responsible for:

 Identifying planned or potential discharges and initiating the ERA process in

consultation with the AzSPU Environmental Manager;

 Collecting the data and identifying resources required for an ERA;

 Undertaking, in consultation with the Central Environmental Team, the initial

assessment of whether an identified planned or potential discharge has received prior

approval;

 Overseeing the initial qualitative risk assessment, including engagement of specialist

contractor(s) to conduct the assessment as required (in consultation with AzSPU

Environmental Manager);

 Initiating and ensuring completion of the quantitative risk assessment, as required;

 Liaising with the AzSPU Environmental Manager with regard requirement for

consultation with Regulators (MENR), and assisting with the consultation as required

under the direction of the AzSPU Environmental Manager;

 Maintaining the Asset Discharge Register; and

 Ensuring ERA requirements are taken into account during the chemical selection

process, as outlined in Section 5.1 of the AzSPU Chemical and Hazardous Materials

Management Procedure (AZSPU-HSSE-DOC-00078-2);

4.2 AzSPU Environmental Manager

The AzSPU Environmental Manager, or their designee, shall be responsible for..

 Assisting the PU/Asset Environmental Team Lead, as requested, in assessing the

need for and scope of an ERA;

 Ensuring the database of all records pertaining to the approval process, i.e. ERA,

permits etc, is maintained, and providing advise to the PU/Asset Environmental

Team Lead as to whether prior approval for discharge has been received;

 Leading consultations with the regulatory authorities regarding environmental

approval of chemicals used and reporting of discharges containing chemicals;

 Ensuring that Asset Environmental Advisors receive adequate training in

environmental risk assessment;

 Ensuring central Register of chemicals approved for discharge is maintained and is

regularly updated;

 Maintaining and updating this procedure, and revision and maintenance of Schedule

of Environmental Statutory Reports in conjunction with the AzSPU HSSE

Compliance Team and Accountable PU(s) / Asset Group(s).

4.3 Asset Operations Supervisor

The applicable PU/Asset Operations Supervisor, or their designee, shall be responsible for:

 Informing PU/Asset Environmental Team Leader/Environment Manager of any

planned or anticipated discharges to the environment;

Control Tier:

<<Tier-2-AzSPU>>

Revision Date: 31 January 2010

Document Number: << AZSPU-HSSE-DOC-00120-2>>

Print Date: 2/1/2011

PAPER COPIES ARE UNCONTROLLED. THIS COPY VALID ONLY AT THE TIME OF PRINTING. THE

CONTROLLED VERSION OF THIS DOCUMENT CAN BE FOUND AT

http://docs.bpweb.bp.com/dkazspu/component/hssesms

Military reference books and manuals (2009-2023, Volume 4) - page 27